<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5490820</article-id><article-id pub-id-type="pmcid-ver">PMC5490820.1</article-id><article-id pub-id-type="pmcaid">5490820</article-id><article-id pub-id-type="pmcaiid">5490820</article-id><article-id pub-id-type="pmid">28608813</article-id><article-id pub-id-type="doi">10.3390/v9060143</article-id><article-id pub-id-type="publisher-id">viruses-09-00143</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>McArthur</surname><given-names initials="MA">Monica A.</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Freed</surname><given-names initials="E">Eric</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-09-00143">Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA; <email>mmcarthu@som.umaryland.edu</email>; Tel.: +1-410-706-5328</aff><pub-date pub-type="epub"><day>13</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2017</year></pub-date><volume>9</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">294558</issue-id><elocation-id>143</elocation-id><history><date date-type="received"><day>18</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>30</day><month>06</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-06 13:25:48.297"><day>06</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2017 by the author.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-09-00143.pdf"/><abstract><p>Zika is a rapidly emerging public health threat. Although clinical infection is frequently mild, significant neurological manifestations have been demonstrated in infants born to Zika virus (ZIKV) infected mothers. Due to the substantial ramifications of intrauterine infection, effective counter-measures are urgently needed. In order to develop effective anti-ZIKV vaccines and therapeutics, improved animal models and a better understanding of immunological correlates of protection against ZIKV are required. This review will summarize what is currently known about ZIKV, the clinical manifestations and epidemiology of Zika as well as, the development of animal models to study ZIKV infection, host immune responses against ZIKV, and the current state of development of vaccines and therapeutics against ZIKV.</p></abstract><kwd-group><kwd>Zika virus</kwd><kwd>animal models</kwd><kwd>immunology</kwd><kwd>vaccines</kwd><kwd>congenital Zika syndrome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-viruses-09-00143"><title>1. Introduction</title><p>As of March 2017, 84 countries and territories have reported evidence of mosquito-borne Zika virus (ZIKV) transmission, including the United States of America [<xref rid="B1-viruses-09-00143" ref-type="bibr">1</xref>]. Furthermore, many of these countries have reported microcephaly and other central nervous system (CNS) malformations potentially associated with ZIKV infection, or suggestive of congenital infection as well as increased incidence of Guillain&#8211;Barr&#233; syndrome (GBS) and/or laboratory confirmation of ZIKV infection among GBS cases [<xref rid="B1-viruses-09-00143" ref-type="bibr">1</xref>]. The temporal association of ZIKV transmission with clusters of microcephaly and GBS was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) on 1 February 2016, a designation which was subsequently ended at the fifth meeting of the Emergency Committee on ZIKV, microcephaly and other neurological disorders on 18 November 2016 [<xref rid="B2-viruses-09-00143" ref-type="bibr">2</xref>,<xref rid="B3-viruses-09-00143" ref-type="bibr">3</xref>]. According to the WHO, the decision was made to escalate the coordination and response to ZIKV to a more sustained program to address the long-term nature of the disease and its consequences [<xref rid="B2-viruses-09-00143" ref-type="bibr">2</xref>]. As ZIKV continues to spread, many &#8220;unknowns&#8221; remain and considerable research is needed to advance our understanding of this important pathogen. The current literature pertaining to the clinical manifestations and epidemiology of ZIKV as well as, the development of animal models to study ZIKV infection, host immune responses against ZIKV, and the current state of development of vaccines and therapeutics against ZIKV will be discussed.</p></sec><sec id="sec2-viruses-09-00143"><title>2. Isolation and Characterization</title><p>ZIKV was first isolated from a sentinel rhesus monkey in Uganda, near the Zika forest, in 1947 [<xref rid="B4-viruses-09-00143" ref-type="bibr">4</xref>]; however, there was limited documentation of human infection prior to the 2007 outbreak on Yap Island in the Federated States of Micronesia [<xref rid="B5-viruses-09-00143" ref-type="bibr">5</xref>]. ZIKV belongs to the family <italic toggle="yes">Flaviviridae</italic>, genus <italic toggle="yes">Flavivirus</italic> and is a mosquito-borne virus in the Spondweni group [<xref rid="B6-viruses-09-00143" ref-type="bibr">6</xref>]. Flaviviruses are among the most medically significant arboviruses and include, in addition to ZIKV, pathogens such as yellow fever virus (YFV), Japanese encephalitis virus (JEV), West Nile Virus (WNV), tick-borne encephalitis virus (TBEV), and the four dengue viruses (DENV1&#8211;4).</p><p>Flaviviruses are enveloped RNA viruses that contain the viral genome complexed with multiple copies of the capsid protein (C) and surrounded by an icosahedral shell composed of 180 copies of the envelope (E) glycoprotein and the membrane (M) or precursor membrane (prM) proteins. The E and M/prM proteins are anchored in a lipid membrane [<xref rid="B7-viruses-09-00143" ref-type="bibr">7</xref>]. The full-length genome of ZIKV is 10,794 nucleotides and encodes 3419 amino acids, which, in addition to the structural proteins (C, prM, and E), constitute seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) [<xref rid="B6-viruses-09-00143" ref-type="bibr">6</xref>,<xref rid="B7-viruses-09-00143" ref-type="bibr">7</xref>]. The non-structural proteins are involved in replication and assembly of the virus as well as antagonizing the host innate immune response [<xref rid="B7-viruses-09-00143" ref-type="bibr">7</xref>]. Specifically, NS3 and NS5 are large, multifunctional proteins which contain several enzymatic activities involved in polyprotein processing (NS3) and RNA replication (NS3 and NS5) [<xref rid="B8-viruses-09-00143" ref-type="bibr">8</xref>]. Additionally, NS5 has been demonstrated to antagonize the interferon (IFN) response [<xref rid="B9-viruses-09-00143" ref-type="bibr">9</xref>].The crystal structure of ZIKV has been solved and demonstrates that the mature ZIKV structure is similar to mature WNV and DENV structures [<xref rid="B7-viruses-09-00143" ref-type="bibr">7</xref>]. However, there are notable differences in the E protein structure which may be responsible for cellular tropism and contribute to disease outcomes [<xref rid="B7-viruses-09-00143" ref-type="bibr">7</xref>]. </p><p>Phylogenetic analyses of ZIKV strains isolated from 1947 to 2016 identified two distinct clades (lineages), African and Asian [<xref rid="B10-viruses-09-00143" ref-type="bibr">10</xref>]. The causative agent of the current ZIKV epidemic belongs to the Asian lineage, which, while not closely related to the African lineage, shares a common ancestor [<xref rid="B10-viruses-09-00143" ref-type="bibr">10</xref>]. Comparisons of the E protein sequences from the two lineages found that the Asian lineage contains insertions in the E protein glycosylation motif which are not present in the African lineage [<xref rid="B10-viruses-09-00143" ref-type="bibr">10</xref>]. When the amino acid sequences of the E protein of ZIKV isolates from human (2015/2016 epidemic), monkey (pre-epidemic), and mosquito (pre-epidemic) were compared, a total of sixteen amino acid substitutions were identified, resulting in subtle structural changes [<xref rid="B10-viruses-09-00143" ref-type="bibr">10</xref>]. These changes, although subtle, may impact ZIKV virulence and host tropism [<xref rid="B10-viruses-09-00143" ref-type="bibr">10</xref>].</p></sec><sec id="sec3-viruses-09-00143"><title>3. Epidemiology</title><p>Despite relatively limited reports of human cases of ZIKV infection from 1947 until the 2007 outbreak on Yap Island, ZIKV has now spread dramatically to include over 80 countries and territories with vector-borne transmission [<xref rid="B1-viruses-09-00143" ref-type="bibr">1</xref>]. Following the introduction of ZIKV to Yap Island, sporadic cases of ZIKV infection continued to be reported in Southeast Asia during the mid-2010s [<xref rid="B11-viruses-09-00143" ref-type="bibr">11</xref>]. A major epidemic of ZIKV infection ensued in French Polynesia in 2013&#8211;2014 and some severe cases were associated with neurological complications such as GBS [<xref rid="B12-viruses-09-00143" ref-type="bibr">12</xref>,<xref rid="B13-viruses-09-00143" ref-type="bibr">13</xref>]. ZIKV was first reported in Brazil in 2015 with large numbers of suspected cases and the initial observation that the number of newborn infants with microcephaly was increased in ZIKV-affected areas later that year [<xref rid="B11-viruses-09-00143" ref-type="bibr">11</xref>]. ZIKV has since spread to include much of Central and South America and the Caribbean. Furthermore, vector-borne transmission of ZIKV has been documented in the US in both Texas and Florida [<xref rid="B14-viruses-09-00143" ref-type="bibr">14</xref>]. </p><p>The primary mode of ZIKV transmission is through the bite of infected mosquitoes, with <italic toggle="yes">Aedes aegypti</italic> and <italic toggle="yes">Aedes albopictus</italic> being the predominant vectors [<xref rid="B6-viruses-09-00143" ref-type="bibr">6</xref>,<xref rid="B15-viruses-09-00143" ref-type="bibr">15</xref>]. While <italic toggle="yes">Ae. aegypti</italic> mosquitoes are confined to tropical and sub-tropical regions, <italic toggle="yes">Ae. albopictus</italic>, are distributed throughout tropical, sub-tropical, and temperate regions [<xref rid="B16-viruses-09-00143" ref-type="bibr">16</xref>]. Since 2015, ZIKV has spread rapidly through the range occupied by <italic toggle="yes">Aedes</italic> mosquitos in the Americas [<xref rid="B15-viruses-09-00143" ref-type="bibr">15</xref>]. In addition to vector-borne transmission, sexual transmission is a contributor to ZIKV spread [<xref rid="B17-viruses-09-00143" ref-type="bibr">17</xref>,<xref rid="B18-viruses-09-00143" ref-type="bibr">18</xref>,<xref rid="B19-viruses-09-00143" ref-type="bibr">19</xref>,<xref rid="B20-viruses-09-00143" ref-type="bibr">20</xref>]. Additional modes of transmission have also been reported, including transmission from mother to child, blood transfusion-related transmission, laboratory transmission, and transmission by physical contact [<xref rid="B16-viruses-09-00143" ref-type="bibr">16</xref>]. </p><p>It is likely that ZIKV will continue to spread; however, it is unclear at this time whether ZIKV transmission will remain epidemic, eventually becoming episodic with intervening periods of relative inactivity, or if it will become endemic with seasonal transmission patterns [<xref rid="B21-viruses-09-00143" ref-type="bibr">21</xref>]. Characterization of the epidemiology of ZIKV is complicated by inadequate diagnostic assays (discussed below) and co-circulation with viruses demonstrating similar clinical presentations (i.e., Chikungunya virus (CHIKV) and DENV) [<xref rid="B22-viruses-09-00143" ref-type="bibr">22</xref>].</p></sec><sec id="sec4-viruses-09-00143"><title>4. Clinical Manifestations</title><p>Most individuals, ~80%, infected with ZIKV are asymptomatic [<xref rid="B23-viruses-09-00143" ref-type="bibr">23</xref>]. When symptoms are present, they are generally mild and may include pruritic maculopapular rash, fever (typically low-grade), arthritis, arthralgia, non-purulent conjunctivitis, and edema of the extremities [<xref rid="B5-viruses-09-00143" ref-type="bibr">5</xref>,<xref rid="B23-viruses-09-00143" ref-type="bibr">23</xref>,<xref rid="B24-viruses-09-00143" ref-type="bibr">24</xref>,<xref rid="B25-viruses-09-00143" ref-type="bibr">25</xref>]. Additional symptoms of headache, myalgia, retro-orbital pain, low-back pain, lymphadenopathy, and vomiting have also been reported [<xref rid="B5-viruses-09-00143" ref-type="bibr">5</xref>,<xref rid="B24-viruses-09-00143" ref-type="bibr">24</xref>]. While disease is frequently mild, fatal cases have been reported, particularly in individuals with underlying medical conditions [<xref rid="B26-viruses-09-00143" ref-type="bibr">26</xref>,<xref rid="B27-viruses-09-00143" ref-type="bibr">27</xref>,<xref rid="B28-viruses-09-00143" ref-type="bibr">28</xref>,<xref rid="B29-viruses-09-00143" ref-type="bibr">29</xref>,<xref rid="B30-viruses-09-00143" ref-type="bibr">30</xref>,<xref rid="B31-viruses-09-00143" ref-type="bibr">31</xref>]. </p><sec id="sec4dot1-viruses-09-00143"><title>4.1. Neurological Manifestations of ZIKV Infection</title><p>A major concern during the current ZIKV epidemic has been the association of ZIKV with neurological complications. GBS is the most frequent neurological sequela reported [<xref rid="B12-viruses-09-00143" ref-type="bibr">12</xref>,<xref rid="B13-viruses-09-00143" ref-type="bibr">13</xref>,<xref rid="B25-viruses-09-00143" ref-type="bibr">25</xref>,<xref rid="B32-viruses-09-00143" ref-type="bibr">32</xref>]. Although GBS is commonly thought to have a good prognosis, up to 20% of GBS patients may remain severely disabled and even with treatment, approximately 5% of GBS cases are fatal [<xref rid="B33-viruses-09-00143" ref-type="bibr">33</xref>]. GBS is characterized by progressive bilateral and relatively symmetric weakness of the limbs frequently with hyporeflexia or areflexia. There is considerable evidence suggesting GBS has an autoimmune etiology [<xref rid="B33-viruses-09-00143" ref-type="bibr">33</xref>]. GBS has previously been associated with preceding infections such as <italic toggle="yes">Campylobacter jejuni</italic>, cytomegalovirus (CMV), Epstein&#8211;Barr virus (EBV), varicella zoster virus (VZV) and <italic toggle="yes">Mycoplasma pneumoniae</italic>. Additionally, there has been a link to influenza vaccination [<xref rid="B34-viruses-09-00143" ref-type="bibr">34</xref>]. The mechanism by which ZIKV infection is associated with GBS remains unknown. It is therefore of critical importance to monitor for GBS in large scale vaccine trials as well as natural infection.</p><p>Other neurological complications associated with ZIKV infection including encephalitis, meningoencephalitis, and acute myelitis have also been reported [<xref rid="B30-viruses-09-00143" ref-type="bibr">30</xref>,<xref rid="B35-viruses-09-00143" ref-type="bibr">35</xref>,<xref rid="B36-viruses-09-00143" ref-type="bibr">36</xref>].</p></sec><sec id="sec4dot2-viruses-09-00143"><title>4.2. Congenital Zika Syndrome</title><p>The Brazil Ministry of Health reported an unusual increase in cases of microcephaly in October and November 2015, the Pan American Health Organization (PAHO) and WHO requested Member States to monitor for similar events [<xref rid="B37-viruses-09-00143" ref-type="bibr">37</xref>]. The identification of an increased number of cases of microcephaly potentially associated with ZIKV prompted the declaration of a PHEIC in February 2016 [<xref rid="B3-viruses-09-00143" ref-type="bibr">3</xref>]. Subsequently, multiple reports of microcephaly and other birth defects following ZIKV infection during pregnancy have been made [<xref rid="B38-viruses-09-00143" ref-type="bibr">38</xref>,<xref rid="B39-viruses-09-00143" ref-type="bibr">39</xref>,<xref rid="B40-viruses-09-00143" ref-type="bibr">40</xref>,<xref rid="B41-viruses-09-00143" ref-type="bibr">41</xref>,<xref rid="B42-viruses-09-00143" ref-type="bibr">42</xref>,<xref rid="B43-viruses-09-00143" ref-type="bibr">43</xref>]. Following recognition of increases in the number of infants with microcephaly in Brazil [<xref rid="B44-viruses-09-00143" ref-type="bibr">44</xref>] and French Polynesia [<xref rid="B40-viruses-09-00143" ref-type="bibr">40</xref>] which were spatially and temporally associated with outbreaks of ZIKV infection, a causal link was suspected [<xref rid="B45-viruses-09-00143" ref-type="bibr">45</xref>]. Subsequently, Rassmussen et al. applied Shepard&#8217;s criteria for causality and suggested that sufficient evidence had been accumulated to infer a causal relationship between ZIKV infection and microcephaly as well as other brain anomalies [<xref rid="B46-viruses-09-00143" ref-type="bibr">46</xref>]. Evidence to support the role of ZIKV infection during pregnancy in causing microcephaly and other neurological malformations includes: (a) temporal association (with a six-month delay) of increases in microcephaly with increased ZIKV transmission [<xref rid="B44-viruses-09-00143" ref-type="bibr">44</xref>]; (b) data modeling indicating the first trimester is the primary risk period of pregnancy [<xref rid="B40-viruses-09-00143" ref-type="bibr">40</xref>]; (c) identification of ZIKV in the brains of fetuses and infants (who died) with microcephaly [<xref rid="B47-viruses-09-00143" ref-type="bibr">47</xref>,<xref rid="B48-viruses-09-00143" ref-type="bibr">48</xref>]; (d) attenuation of human neural progenitor cell growth following in vitro ZIKV infection [<xref rid="B49-viruses-09-00143" ref-type="bibr">49</xref>]; (e) in vitro infection of placental macrophages and cytotrophoblasts [<xref rid="B50-viruses-09-00143" ref-type="bibr">50</xref>]; and (f) evidence of microcephaly associated with ZIKV infection in mouse and non-human primate models [<xref rid="B51-viruses-09-00143" ref-type="bibr">51</xref>,<xref rid="B52-viruses-09-00143" ref-type="bibr">52</xref>,<xref rid="B53-viruses-09-00143" ref-type="bibr">53</xref>,<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>]. </p></sec></sec><sec id="sec5-viruses-09-00143"><title>5. Animal Models</title><p>Animal models play an important role in understanding viral pathogenesis, identifying promising vaccine candidates, and testing therapeutics. The scientific community has exerted considerable effort in developing animal models which recapitulate various aspects of human ZIKV infection and disease. For a comprehensive review of animal models for ZIKV infection and Zika disease, see Morrison and Diamond [<xref rid="B55-viruses-09-00143" ref-type="bibr">55</xref>].</p><sec id="sec5dot1-viruses-09-00143"><title>5.1. Rodent Models</title><p>Initial attempts to infect wild-type (wt) mice with ZIKV resulted in infection only by the intra-cerebral (ic) route [<xref rid="B4-viruses-09-00143" ref-type="bibr">4</xref>]; however, passage through mouse brain resulted in adaptation to the mouse model [<xref rid="B56-viruses-09-00143" ref-type="bibr">56</xref>]. Similarly, guinea pigs and rabbits did not show signs of disease following inoculation with ZIKV [<xref rid="B56-viruses-09-00143" ref-type="bibr">56</xref>]. Although adult immunocompetent mice do not typically develop overt signs of clinical disease, wt mice have been used to demonstrate intrauterine infection [<xref rid="B52-viruses-09-00143" ref-type="bibr">52</xref>,<xref rid="B57-viruses-09-00143" ref-type="bibr">57</xref>]. Additionally, treatment of wt mice with antibodies blocking aspects of the interferon (IFN) response have been used as described below [<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>,<xref rid="B58-viruses-09-00143" ref-type="bibr">58</xref>,<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>]. More recently immunocompromised mouse models, mostly lacking IFN responses, have been utilized to study systemic infection with ZIKV [<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>,<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>,<xref rid="B60-viruses-09-00143" ref-type="bibr">60</xref>,<xref rid="B61-viruses-09-00143" ref-type="bibr">61</xref>,<xref rid="B62-viruses-09-00143" ref-type="bibr">62</xref>]. A variety of mouse models which lack various components of the IFN response have been employed, including A129 (lack IFN &#945;/&#946; receptor and are, therefore, incapable of responding to Type I IFN) [<xref rid="B61-viruses-09-00143" ref-type="bibr">61</xref>,<xref rid="B62-viruses-09-00143" ref-type="bibr">62</xref>], AG129 (lack Type I and II IFN responsiveness) [<xref rid="B60-viruses-09-00143" ref-type="bibr">60</xref>,<xref rid="B62-viruses-09-00143" ref-type="bibr">62</xref>], <italic toggle="yes">Irf3</italic><sup>&#8722;/&#8722;</sup>
<italic toggle="yes">Irf5</italic><sup>&#8722;/&#8722;</sup>
<italic toggle="yes">Irf7</italic><sup>&#8722;/&#8722;</sup> (triple knockouts which produce very little IFN &#945;/&#946;) [<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>], <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> (lack IFN-&#945;/&#946; receptor) [<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>,<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>]. Interestingly, while Lazear et al., reported severe neurological disease in <italic toggle="yes">Irf3</italic><sup>&#8722;/&#8722;</sup>
<italic toggle="yes">Irf5</italic><sup>&#8722;/&#8722;</sup>
<italic toggle="yes">Irf7</italic><sup>&#8722;/&#8722;</sup> triple knock-out (TKO) and <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice following subcutaneous inoculation with either a contemporary human isolate from French Polynesia (H/PF/2013) or the original Ugandan ZIKV strain (MR766), they found no overt disease in <italic toggle="yes">Irf3</italic><sup>&#8722;/&#8722;</sup>, <italic toggle="yes">Irf</italic>
<sup>&#8722;/&#8722;</sup>, and <italic toggle="yes">Mavs</italic><sup>&#8722;/&#8722;</sup> single knock-out mice [<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>]. Despite the fact that both H/PF/2013 and MR766 elicited neurological disease in these models, H/PF/2013 demonstrated greater pathogenicity than the original Ugandan strain, MR766. Following intravenous inoculation, <italic toggle="yes">Irf3</italic><sup>&#8722;/&#8722;</sup>
<italic toggle="yes">Irf5</italic><sup>&#8722;/&#8722;</sup>
<italic toggle="yes">Irf7</italic><sup>&#8722;/&#8722;</sup> TKO were more susceptible to ZIKV infection than <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice indicating a potential role for IRF-3-dependent, IFN-&#945;/&#946;-independent restriction mechanisms [<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>]. Furthermore, wt mice treated with MAR1-5A3 (a monoclonal antibody (mAb) that blocks the IFN-&#945;/&#946; receptor (IFNAR)) were susceptible to ZIKV infection but did not demonstrate a same neurological phenotype as <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice [<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>]. Additionally, mice immunosuppressed by treatment with dexamethasone developed ZIKV infection when inoculated with a clinical ZIKV isolate from Puerto Rico (PRVABC59) and treatment with type I IFN resulted in improved clinical outcome [<xref rid="B63-viruses-09-00143" ref-type="bibr">63</xref>]. Taken together, these studies indicate an important role for the IFN response in protection against ZIKV infection.</p><p>Perhaps even more important than models of systemic ZIKV infection, are models of ZIKV infection during pregnancy. Multiple mouse models for ZIKV infection during pregnancy have been proposed. The <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> and MAR1-5A3 blocking models were used by Miner et al. to investigate ZIKV replication and trans-placental transmission in pregnant dams following infection with a clinical isolate from French Polynesia (H/PF/2013) [<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>]. Infection of <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> dams mated with wt males resulted in fetal demise, while when pregnant wt dams were given anti-IFNAR mAb prior to and during infection, there was mild intrauterine growth restriction (IUGR) and viral infection within the fetal head during a key period of neurodevelopment [<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>]. Another study using wt mice (SJL and C57BL/6 strains) found that infection of pregnant SJL mice with a Brazilian strain of ZIKV intravenously (iv) resulted in IUGR and ZIKV RNA was identified in multiple fetal tissues, particularly the brain [<xref rid="B52-viruses-09-00143" ref-type="bibr">52</xref>]. Furthermore, surviving fetuses demonstrated cortical malformations with reduced cell number and cortical layer thickness (both signs associated with microcephaly in humans) as well as ocular abnormalities [<xref rid="B52-viruses-09-00143" ref-type="bibr">52</xref>]. Adult C57 mice inoculated intra-peritoneally (ip) with a contemporary clinical ZIKV isolate were also able to transmit virus to their unborn fetuses and resulted in infection of primary neural progenitor cells responsible for cortex development as well as reduction of these cortex founder cells in the fetuses [<xref rid="B57-viruses-09-00143" ref-type="bibr">57</xref>]. Intravaginal exposure to a Cambodian ZIKV strain, FSS13025, in both wt and <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice demonstrated replication of the virus in the vaginal mucosa (higher levels were identified in <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice) which resulted in IUGR and fetal brain infection (wt mice) and severe IUGR and fetal death (<italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice) [<xref rid="B64-viruses-09-00143" ref-type="bibr">64</xref>]. Direct infection of embryonic brains has also been demonstrated, and an Asian ZIKV strain, SZ01, was found to infect neural progenitor cells and cause cell death resulting in microcephaly [<xref rid="B53-viruses-09-00143" ref-type="bibr">53</xref>]. Additionally, transcriptomic analyses following ZIKV infection demonstrated enrichment of up-regulated immune-response-related and apoptosis pathways providing further evidence that cytokines may play a role in ZIKV pathogenesis [<xref rid="B53-viruses-09-00143" ref-type="bibr">53</xref>]. In sum, studies in mice have demonstrated that the interferon response is likely to play a critical role in protection from or susceptibility to ZIKV infection. While these studies support a causal role for ZIKV infection during pregnancy and microcephaly/neurological malformations, it is important to note that there are considerable differences in the morphological, spatial, and temporal placentation between mice and humans as well as differences in in utero brain development [<xref rid="B65-viruses-09-00143" ref-type="bibr">65</xref>,<xref rid="B66-viruses-09-00143" ref-type="bibr">66</xref>]. Further efforts to develop novel and enhance existing animal models to better recapitulate human disease are needed.</p></sec><sec id="sec5dot2-viruses-09-00143"><title>5.2. Non-Human Primate (NHP)Models</title><p>While mice represent a relatively easy to study small animal model for ZIKV, the previously mentioned differences between humans and mice necessitate additional models of disease. Immunocompetent macaque monkeys have similar gestation and fetal development to humans providing an animal model that more faithfully recapitulates human disease [<xref rid="B51-viruses-09-00143" ref-type="bibr">51</xref>,<xref rid="B67-viruses-09-00143" ref-type="bibr">67</xref>,<xref rid="B68-viruses-09-00143" ref-type="bibr">68</xref>,<xref rid="B69-viruses-09-00143" ref-type="bibr">69</xref>]. In non-pregnant rhesus macaques, the duration of detectable viral RNA in plasma is similar to that in humans, 6&#8211;7 days post infection, and the decline in plasma levels of viral RNA is coincident with increases in anti-ZIKV neutralizing antibody titers [<xref rid="B69-viruses-09-00143" ref-type="bibr">69</xref>]. Dudley et al., have recently demonstrated prolonged viremia following infection with an Asian lineage ZIKV in pregnant rhesus macaques compared to non-pregnant animals [<xref rid="B67-viruses-09-00143" ref-type="bibr">67</xref>]. Furthermore, they identified ZIKV-specific proliferation of natural killer (NK) cells and adaptive immune responses, including proliferation of CD4+ and CD8+ T cells, circulating plasmablasts, and ZIKV-specific IFN-&#947; production (by Elispot) [<xref rid="B67-viruses-09-00143" ref-type="bibr">67</xref>]. ZIKV RNA has also been detected in placenta, fetal brain and liver as well as maternal tissues following infection of a pigtail macaque with an Asian lineage ZIKV [<xref rid="B51-viruses-09-00143" ref-type="bibr">51</xref>]. Additionally, Magnetic Resonance Imaging (MRI) abnormalities in the fetal brain were identified 10 days after inoculation suggesting that fetal brain injury begins shortly after infection [<xref rid="B51-viruses-09-00143" ref-type="bibr">51</xref>]. In a recent study by Osuna et al., both rhesus and cynomolgus macaques were shown to be highly susceptible to ZIKV infection following subcutaneous (sc) inoculation with isolates of Thai and Puerto Rican origin [<xref rid="B68-viruses-09-00143" ref-type="bibr">68</xref>]. Activation of T and B cells was reported and multiple animals developed T cells specific for ZIKV peptides as evidenced by cytokine production following in vitro stimulation [<xref rid="B68-viruses-09-00143" ref-type="bibr">68</xref>]. Studies utilizing non-human primate models to test anti-ZIKV vaccine candidates will be discussed below.</p></sec></sec><sec id="sec6-viruses-09-00143"><title>6. Immunology</title><sec id="sec6dot1-viruses-09-00143"><title>6.1. Innate Immunity</title><p>Early responses by the innate immune system are the first line of host defense for the suppression of viral infections. IFN production is a major component of the innate response and the transcriptional regulation of numerous IFN-regulated genes leads to an antiviral environment [<xref rid="B70-viruses-09-00143" ref-type="bibr">70</xref>]. As previously discussed, mice deficient in various components of the IFN response have increased susceptibility to ZIKV infection compared to wt mice [<xref rid="B54-viruses-09-00143" ref-type="bibr">54</xref>,<xref rid="B59-viruses-09-00143" ref-type="bibr">59</xref>,<xref rid="B60-viruses-09-00143" ref-type="bibr">60</xref>,<xref rid="B61-viruses-09-00143" ref-type="bibr">61</xref>,<xref rid="B62-viruses-09-00143" ref-type="bibr">62</xref>,<xref rid="B64-viruses-09-00143" ref-type="bibr">64</xref>]. It has been shown that human primary trophoblast cells, isolated from full-term placentas, constitutively release antiviral type III IFN&#955;1 which acts in both autocrine and paracrine fashion to protect cells from ZIKV infection [<xref rid="B71-viruses-09-00143" ref-type="bibr">71</xref>]. These in vitro data suggest that ZIKV may not access the fetal compartment by direct replication in placental syncytiotrophoblasts during later stages of pregnancy [<xref rid="B71-viruses-09-00143" ref-type="bibr">71</xref>]. However, it remains to be determined whether first-trimester trophoblasts are more permissive to ZIKV infection than late pregnancy villous trophoblasts and/or the antiviral effects of IFN&#955;s [<xref rid="B71-viruses-09-00143" ref-type="bibr">71</xref>]. Importantly, there are significant differences in the type III IFN pathway between mice and humans potentially complicating the interpretation of mouse models of ZIKV during pregnancy [<xref rid="B71-viruses-09-00143" ref-type="bibr">71</xref>]. Flaviviruses have previously been shown to antagonize IFN signaling through multiple mechanisms [<xref rid="B72-viruses-09-00143" ref-type="bibr">72</xref>]. In vitro studies have demonstrated that ZIKV NS5 binds to and targets the human IFN-regulated transcriptional activator STAT2 for proteasomal degradation; in contrast, mouse STAT2 is refractory to ZIKV NS5 [<xref rid="B73-viruses-09-00143" ref-type="bibr">73</xref>]. NS5-mediated degradation of STAT2 has also been demonstrated for DENV, but the mechanisms of degradation differ between DENV and ZIKV [<xref rid="B73-viruses-09-00143" ref-type="bibr">73</xref>]. Interestingly, although Type I and Type III IFN use different cell-surface receptors they both signal through the Janus kinases-signal transducers and activators of transcription (Jak-STAT) pathway, including STAT2 [<xref rid="B73-viruses-09-00143" ref-type="bibr">73</xref>,<xref rid="B74-viruses-09-00143" ref-type="bibr">74</xref>]. For this reason, it is possible that while, Type III IFN are produced by villous trophoblasts [<xref rid="B71-viruses-09-00143" ref-type="bibr">71</xref>], ZIKV may be able to evade Type III IFN signaling by degrading STAT2 mediated by NS5 [<xref rid="B73-viruses-09-00143" ref-type="bibr">73</xref>]. In a mouse model of intravaginal ZIKV infection, it was demonstrated that antiviral Type I and III IFN and other inflammatory mediators were poorly induced and that there was robust viral replication in the vaginal mucosa [<xref rid="B75-viruses-09-00143" ref-type="bibr">75</xref>]. Viral replication has also been shown in the vaginal mucosa of wt pregnant mice with even higher levels of viral replication demonstrated in <italic toggle="yes">Ifnar1</italic><sup>&#8722;/&#8722;</sup> mice [<xref rid="B64-viruses-09-00143" ref-type="bibr">64</xref>]. Furthermore, Khan et al. found that if the dampened innate immune response was augmented (either by systemic infection with an unrelated pathogen or vaginal administration of acitretin) ZIKV replication was inhibited [<xref rid="B75-viruses-09-00143" ref-type="bibr">75</xref>]. Taken together with studies using various strains of IFN-deficient mice, these data indicate a critical role for IFN in resistance to ZIKV infection.</p></sec><sec id="sec6dot2-viruses-09-00143"><title>6.2. Humoral Immunity</title><p>Neutralizing antibodies are thought to be a major factor in the protection against ZIKV infection [<xref rid="B76-viruses-09-00143" ref-type="bibr">76</xref>,<xref rid="B77-viruses-09-00143" ref-type="bibr">77</xref>,<xref rid="B78-viruses-09-00143" ref-type="bibr">78</xref>]. In fact, broadly neutralizing human monoclonal antibodies directed against the E protein were protective against ZIKV-infection in type I/II interferon receptor-knockout mice [<xref rid="B78-viruses-09-00143" ref-type="bibr">78</xref>]. However, these mAb were initially derived from DENV-infected individuals, not ZIKV-infected individuals. In another study, Sapparapu et al. isolated a panel of human mAb from individuals infected with ZIKV and identified a potent neutralizing antibody recognizing a quaternary epitope of the E protein dimer-dimer interface [<xref rid="B76-viruses-09-00143" ref-type="bibr">76</xref>]. This mAb was also found to protect anti-IFNAR1 treated C57BL/6 mice from challenge with a mouse-adapted strain of ZIKV [<xref rid="B76-viruses-09-00143" ref-type="bibr">76</xref>]. Furthermore, passive transfer of anti-ZIKV antibodies elicited by immunization has been shown to be protective in mice [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>,<xref rid="B80-viruses-09-00143" ref-type="bibr">80</xref>]. </p><p>Antibodies against flaviviruses tend to be highly cross-reactive [<xref rid="B81-viruses-09-00143" ref-type="bibr">81</xref>] and ZIKV is no exception. In fact, serological diagnosis has been complicated by a lack of ZIKV-specific antibody based assays. Both ELISA and Plaque Reduction Neutralization Tests (PRNT) demonstrate significant cross-reactivity with related viruses, including DENV which co-circulates in many of the areas affected by the current ZIKV epidemic [<xref rid="B82-viruses-09-00143" ref-type="bibr">82</xref>]. Multiple groups have identified antibodies from DENV patients, which cross-react, and in some cases, neutralize ZIKV [<xref rid="B78-viruses-09-00143" ref-type="bibr">78</xref>,<xref rid="B83-viruses-09-00143" ref-type="bibr">83</xref>,<xref rid="B84-viruses-09-00143" ref-type="bibr">84</xref>,<xref rid="B85-viruses-09-00143" ref-type="bibr">85</xref>,<xref rid="B86-viruses-09-00143" ref-type="bibr">86</xref>]. Barba-Spaeth et al. identified a subset of ZIKV-neutralizing antibodies that target a conformational epitope and reported the crystal structure of two of these antibodies in complex with the ZIKV E protein to reveal an epitope conserved between DENV and ZIKV [<xref rid="B83-viruses-09-00143" ref-type="bibr">83</xref>]. These structural details of a conserved quaternary epitope may provide an important antigenic target for the development of cross-protective vaccines [<xref rid="B83-viruses-09-00143" ref-type="bibr">83</xref>].</p><p>Although neutralizing antibodies may provide protection against ZIKV infection, there is also concern for antibody dependent enhancement (ADE) which may occur due to cross-reactive, poorly neutralizing antibodies. ADE is an immunological phenomenon in which non-neutralizing or weakly neutralizing antibodies facilitate viral entrance into Fc-receptor bearing cells such as monocytes and macrophages and has been described extensively in the context of secondary DENV infection [<xref rid="B87-viruses-09-00143" ref-type="bibr">87</xref>,<xref rid="B88-viruses-09-00143" ref-type="bibr">88</xref>,<xref rid="B89-viruses-09-00143" ref-type="bibr">89</xref>,<xref rid="B90-viruses-09-00143" ref-type="bibr">90</xref>]. While there has, to date, been no indication in epidemiological studies that prior DENV infection results in ADE of ZIKV infection or disease, in vitro analyses of ZIKV cross-reactive antibodies from DENV-infected individuals have demonstrated enhanced ZIKV infection through an Fc receptor-mediated process [<xref rid="B84-viruses-09-00143" ref-type="bibr">84</xref>,<xref rid="B86-viruses-09-00143" ref-type="bibr">86</xref>]. In AG129 (immunocompromised) mice, a DENV cross-reactive anti-ZIKV mAb enhanced DENV2 infection and disease; however, the LALA version of the mAb, which lacks the ability to bind to the Fc receptor, did not enhance disease [<xref rid="B77-viruses-09-00143" ref-type="bibr">77</xref>]. While evidence of ADE has been demonstrated in vitro and in mouse models, extensive epidemiological studies are required to determine the clinical significance of ADE in areas where ZIKV and DENV co-circulate.</p></sec><sec id="sec6dot3-viruses-09-00143"><title>6.3. Cell Mediated Immunity</title><p>While significant information is emerging regarding humoral responses against ZIKV, there have been relatively few studies that explore cell mediated immune (CMI) responses against ZIKV. Data from DENV infection have demonstrated that T cell responses contribute to protection and/or disease enhancement [<xref rid="B91-viruses-09-00143" ref-type="bibr">91</xref>,<xref rid="B92-viruses-09-00143" ref-type="bibr">92</xref>,<xref rid="B93-viruses-09-00143" ref-type="bibr">93</xref>,<xref rid="B94-viruses-09-00143" ref-type="bibr">94</xref>,<xref rid="B95-viruses-09-00143" ref-type="bibr">95</xref>]. Similarly, strong CD4+ and CD8+ T cell responses against the live-attenuated YFV vaccine, 17D have been established [<xref rid="B96-viruses-09-00143" ref-type="bibr">96</xref>,<xref rid="B97-viruses-09-00143" ref-type="bibr">97</xref>,<xref rid="B98-viruses-09-00143" ref-type="bibr">98</xref>]. CMI responses against flaviviruses including JEV and WNV have also been reported [<xref rid="B99-viruses-09-00143" ref-type="bibr">99</xref>,<xref rid="B100-viruses-09-00143" ref-type="bibr">100</xref>]. Rivino et al. presented the argument that due to the high degree of sequence homology among DENV and ZIKV, some of the HLA-restricted CD8+ T cell epitopes may be conserved [<xref rid="B92-viruses-09-00143" ref-type="bibr">92</xref>].</p><p>ZIKV-specific T cell responses have been elaborated in animal models [<xref rid="B67-viruses-09-00143" ref-type="bibr">67</xref>,<xref rid="B68-viruses-09-00143" ref-type="bibr">68</xref>,<xref rid="B80-viruses-09-00143" ref-type="bibr">80</xref>,<xref rid="B101-viruses-09-00143" ref-type="bibr">101</xref>,<xref rid="B102-viruses-09-00143" ref-type="bibr">102</xref>,<xref rid="B103-viruses-09-00143" ref-type="bibr">103</xref>] and humans [<xref rid="B77-viruses-09-00143" ref-type="bibr">77</xref>]. In the NHP model, both CD4+ and CD8+ T cells were expanded as plasma viral RNA loads decreased following infection of rhesus macaques with an Asian lineage ZIKV strain. Additionally, IFN-&#947; secretion was detected in response to in vitro stimulation of peripheral blood mononuclear cells (PBMC) isolated from infected animals with overlapping peptides from the ZIKV NS5 [<xref rid="B67-viruses-09-00143" ref-type="bibr">67</xref>]. Furthermore, increased expression of CD69 (a marker of early T cell activation) by T cells occurred following ZIKV infection and peaked between Days 2 and 5 post-infection [<xref rid="B68-viruses-09-00143" ref-type="bibr">68</xref>]. ZIKV-specific cytokine production by CD4+ and CD8+ T cells was identified in both PBMC and lymph nodes of ZIKV-infected NHP at multiple time-points post-infection with peak responses noted on day 28 post-infection [<xref rid="B68-viruses-09-00143" ref-type="bibr">68</xref>]. Elong Ngono et al. recently used mouse models to begin to dissect the CD8+ T cell responses against ZIKV[<xref rid="B58-viruses-09-00143" ref-type="bibr">58</xref>]. They identified increases in antigen-experienced CD8+ T cells in mice infected with both African (MR766) and Asian (FSS13025) strains of ZIKV [<xref rid="B58-viruses-09-00143" ref-type="bibr">58</xref>]. Moreover, they identified ZIKV-derived epitopes recognized by CD8+ T cells which encompassed peptides from the majority of the ZIKV proteins with a predominance of E protein-derived epitopes [<xref rid="B58-viruses-09-00143" ref-type="bibr">58</xref>]. These ZIKV-responsive CD8+ T cells were multifunctional and also found to mediate cytotoxicity [<xref rid="B58-viruses-09-00143" ref-type="bibr">58</xref>]. Furthermore, depletion of CD8+ T cells resulted in increased levels of infectious ZIKV in the serum and multiple tissues, including the brain [<xref rid="B58-viruses-09-00143" ref-type="bibr">58</xref>]. In humans, CD4+ T cell responses against the ZIKV NS1 protein have been demonstrated [<xref rid="B77-viruses-09-00143" ref-type="bibr">77</xref>]. These T cell responses were primarily in the CXCR3+ compartment and were poorly cross-reactive with DENV [<xref rid="B77-viruses-09-00143" ref-type="bibr">77</xref>]. Although much remains to be learned about the T cell responses against ZIKV, current data support an important role for T cells in protection against ZIKV. </p></sec></sec><sec id="sec7-viruses-09-00143"><title>7. Diagnostics</title><p>The development of diagnostic tests for ZIKV has proven challenging due, in part, to serological cross-reactivity among flaviviruses [<xref rid="B104-viruses-09-00143" ref-type="bibr">104</xref>,<xref rid="B105-viruses-09-00143" ref-type="bibr">105</xref>]. There are currently no US Food and Drug Administration (FDA) approved ZIKV diagnostic tests; however, both serologic and nucleic acid amplification tests (NAAT) including the immunoglobulin (Ig)M class capture enzyme-linked immunosorbent assay (MAC-ELISA) and the Trioplex reverse transcription polymerase chain reaction (RT-PCR) have been given Emergency Use Authorization (EUA) by the FDA [<xref rid="B106-viruses-09-00143" ref-type="bibr">106</xref>]. In addition to these diagnostic tests given EUA, there are numerous research-based assays; however, these assays do not provide validation using the most recent viral strains and fully documented clinical specimens [<xref rid="B104-viruses-09-00143" ref-type="bibr">104</xref>]. </p><sec id="sec7dot1-viruses-09-00143"><title>7.1. Serological Tests</title><p>Due to the complexities of serological diagnostic testing for ZIKV infection, interim guidance for the interpretation of ZIKV antibody test results has been published [<xref rid="B107-viruses-09-00143" ref-type="bibr">107</xref>]. Huzly et al. demonstrated high specificity of the Eurimmun ZIKV ELISA in European individuals with previous flavivirus exposure (either from infection or vaccination) including TBEV, DENV, and YFV [<xref rid="B108-viruses-09-00143" ref-type="bibr">108</xref>]. However, a very recent study demonstrated high levels of cross-reactivity using commercially available DENV ELISA kits [<xref rid="B109-viruses-09-00143" ref-type="bibr">109</xref>]. In this study, 100% of convalescent samples from NAAT confirmed ZIKV-infected individuals demonstrated cross-reactivity with DENV [<xref rid="B109-viruses-09-00143" ref-type="bibr">109</xref>]. Although there is still some risk of cross-reactivity, the plaque reduction neutralization test remains the most specific serological method for diagnosing flaviviruses, including ZIKV [<xref rid="B104-viruses-09-00143" ref-type="bibr">104</xref>]. An ELISA using the ZIKV NS1 antigen has been proposed as a more specific serological test [<xref rid="B110-viruses-09-00143" ref-type="bibr">110</xref>]. In an initial study of sera from individuals with either RT-PCR confirmed or suspected ZIKV infection, sensitivity of combined IgG and IgM ELISA was 100% if samples were obtained &#8805;6 days post-symptom onset [<xref rid="B110-viruses-09-00143" ref-type="bibr">110</xref>]. Furthermore, there was extremely limited cross-reactivity with sera from known DENV, WNV, JEV infected or YFV vaccinated individuals (specificity of 99.8%) [<xref rid="B110-viruses-09-00143" ref-type="bibr">110</xref>]. The significant cross-reactivity demonstrated by most serological tests has hindered diagnosis in areas were multiple flaviviruses co-circulate. Development of serological tests with improved specificity is essential for assessing prevalence of ZIKV infection and aiding in diagnosis. </p></sec><sec id="sec7dot2-viruses-09-00143"><title>7.2. NAAT</title><p>NAAT to detect ZIKV RNA in the serum, whole blood, urine, and cerebrospinal fluid (CSF) are available [<xref rid="B105-viruses-09-00143" ref-type="bibr">105</xref>]. While NAAT are more specific than serological tests, they are limited by the short duration of RNAemia and RNAuria. In general, ZIKV RNA is detectable from serum for approximately seven days post-infection and in urine for approximately 15&#8211;20 days post-infection [<xref rid="B111-viruses-09-00143" ref-type="bibr">111</xref>]. The sensitivity of different NAAT varies. In a comparison of seven published and two new RT-PCR assays, Corman et al. found that some published RT-PCR assays may be of limited value for diagnostics in the current outbreak due to lack of sensitivity or difficulty in obtaining necessary reagents [<xref rid="B112-viruses-09-00143" ref-type="bibr">112</xref>]. Currently, 12 molecular assays are available through EUA [<xref rid="B106-viruses-09-00143" ref-type="bibr">106</xref>].</p></sec></sec><sec id="sec8-viruses-09-00143"><title>8. Vaccines</title><p>It is widely accepted that vaccines provide a cost-effective method of preventing infectious diseases [<xref rid="B113-viruses-09-00143" ref-type="bibr">113</xref>]. Given the rapid spread of and severe outcomes associated with ZIKV infection, the development of a safe and efficacious vaccine is critical. The existence of successful vaccines against other flaviviral diseases (YFV, JEV, DENV, and TBEV) indicates that it is possible to develop a vaccine against ZIKV. Forty-five ZIKV vaccine candidates consisting of multiple vaccine platforms are currently under consideration and at various stages of development as summarized in the WHO vaccine pipeline tracker [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>]. Five candidate vaccines, including inactivated whole organism, DNA, synthetic peptide, and mRNA platforms are already in Phase I clinical trials (<xref ref-type="table" rid="viruses-09-00143-t001">Table 1</xref>) and larger Phase II and III studies are planned pending the results of the Phase I trials [<xref rid="B21-viruses-09-00143" ref-type="bibr">21</xref>]. Due to the large number of vaccine candidates under investigation, this review will focus on those in clinical trials or for which animal model data is available.</p><sec id="sec8dot1-viruses-09-00143"><title>8.1. Inactivated Whole Organism (with or without Adjuvant)</title><p>Several developers are focusing on inactivated whole organism vaccine candidates [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>]. Inactivated vaccines against flaviviruses including JEV and TBEV have been used successfully providing support for this method [<xref rid="B115-viruses-09-00143" ref-type="bibr">115</xref>,<xref rid="B116-viruses-09-00143" ref-type="bibr">116</xref>]. Benefits of an inactivated whole organism vaccine include multiple antigenic targets and non-replicating virus, which may improve safety. Purified inactivated virus (PIV) derived from a Puerto Rican strain of ZIKV was tested in Balb/c mice which received 1 &#181;g of PIV vaccine with alum by either the intramuscular or subcutaneous route or sham inoculated with alum alone [<xref rid="B117-viruses-09-00143" ref-type="bibr">117</xref>]. The PIV vaccine was shown to induce ZIKV-specific neutralizing antibodies after a single immunization and complete protection against ZIKV viremia was observed in those mice that received intramuscular injection [<xref rid="B117-viruses-09-00143" ref-type="bibr">117</xref>]. It is important, however, as mentioned above, to note the limitations of this mouse model in recapitulating human disease. In recent studies by Abbink et al., 16 rhesus monkeys were immunized subcutaneously with 5 &#181;g of ZIKV PIV with alum as an adjuvant or sham inoculated. It was demonstrated that all PIV inoculated animals developed both E protein-specific antibodies as well as neutralizing antibodies [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>]. Furthermore, all PIV-inoculated monkeys were protected against challenge with wild-type ZIKV and had no detectable virus by RT-PCR in blood, urine, CSF, colorectal, or cervicovaginal secretions [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>]. All sham inoculated monkeys had detectable viremia and in the majority, virus was detected in other body fluids as well [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>]. In order to improve vaccine accessibility and reduce manufacturing costs, Yang et al. very recently proposed a cDNA clone-launched platform for high yield production of inactivated ZIKV vaccines [<xref rid="B118-viruses-09-00143" ref-type="bibr">118</xref>]. Currently, Phase I trials of anti-ZIKV PIV vaccine candidates are underway (<xref ref-type="table" rid="viruses-09-00143-t001">Table 1</xref>) [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>,<xref rid="B119-viruses-09-00143" ref-type="bibr">119</xref>]. </p></sec><sec id="sec8dot2-viruses-09-00143"><title>8.2. DNA</title><p>DNA vaccines have been in development since the early 1990s and consist of a selected gene sequence cloned into a plasmid backbone. The plasmid is injected allowing DNA to be taken up by antigen presenting cells, which then express the plasmid-encoded genes to generate the target antigen(s) [<xref rid="B120-viruses-09-00143" ref-type="bibr">120</xref>]. A candidate DNA vaccine against WNV was previously tested in humans and demonstrated excellent safety and immunogenicity [<xref rid="B121-viruses-09-00143" ref-type="bibr">121</xref>,<xref rid="B122-viruses-09-00143" ref-type="bibr">122</xref>]. A monovalent (DENV1) DNA vaccine candidate was also found to have an excellent safety profile in a Phase I clinical trial; however, it did not induce high levels of neutralizing antibodies [<xref rid="B123-viruses-09-00143" ref-type="bibr">123</xref>]. Multiple ZIKV DNA vaccine candidates are in Phase I clinical trials (<xref ref-type="table" rid="viruses-09-00143-t001">Table 1</xref>) [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>,<xref rid="B124-viruses-09-00143" ref-type="bibr">124</xref>]. These DNA vaccine candidates encode the <italic toggle="yes">prM/E</italic> genes of ZIKV. The E protein, in particular, is thought to be a major antigen against which neutralizing antibodies are produced and is considered important for protective efficacy in flaviviral vaccines [<xref rid="B21-viruses-09-00143" ref-type="bibr">21</xref>]. In mice, a single immunization with DNA vaccine candidate encoding prM/E elicited higher E-specific antibody titers than did a DNA vaccine candidate encoding only E indicating the importance of prM in immunogenicity [<xref rid="B117-viruses-09-00143" ref-type="bibr">117</xref>]. Furthermore, the prM/E DNA vaccine induced CD4+ and CD8+ T lymphocyte responses against E as demonstrated by increased IFN-&#947; production by intracellular cytokine staining [<xref rid="B117-viruses-09-00143" ref-type="bibr">117</xref>]. Multiple anti-ZIKV DNA vaccine candidates induce both binding and neutralizing anti-ZIKV antibodies in rhesus monkeys [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>,<xref rid="B80-viruses-09-00143" ref-type="bibr">80</xref>,<xref rid="B125-viruses-09-00143" ref-type="bibr">125</xref>]. </p></sec><sec id="sec8dot3-viruses-09-00143"><title>8.3. RNA</title><p>RNA vaccines contain an open reading frame encoding the antigen of interest which is then translated by the host cellular machinery [<xref rid="B126-viruses-09-00143" ref-type="bibr">126</xref>]. Because there is not the potential for genome integration, RNA-based vaccines may have a safety advantage over DNA vaccines [<xref rid="B102-viruses-09-00143" ref-type="bibr">102</xref>]. Immunogenicity of several RNA vaccine candidates in animal models have been reported in the literature [<xref rid="B102-viruses-09-00143" ref-type="bibr">102</xref>,<xref rid="B103-viruses-09-00143" ref-type="bibr">103</xref>,<xref rid="B127-viruses-09-00143" ref-type="bibr">127</xref>]. A lipid nanoparticle encapsulated modified mRNA encoding prM/E from an Asian lineage ZIKV strain was shown to protect both AG129 mice as well as C57BL/6 mice treated with blocking anti-IFNAR1 antibody (to create a lethal challenge model) [<xref rid="B127-viruses-09-00143" ref-type="bibr">127</xref>]. Richner et al., further modified the mRNA to delete an immunodominant epitope within the E domain II fusion loop and demonstrated that the fusion loop mutant elicited serum antibody responses and protected against ZIKV challenge in mice. Furthermore, the antibodies elicited by the fusion loop mutant caused less ADE of DENV1 infection in cell culture and less immune enhancement of DENV2 infection in AG129 mice [<xref rid="B127-viruses-09-00143" ref-type="bibr">127</xref>]. Another recently reported anti-ZIKV RNA nanoparticle vaccine candidate encoding the prM/E proteins of an Asian lineage ZIKV induced both antibody and CD8+ T cell responses in C57BL/6 mice [<xref rid="B102-viruses-09-00143" ref-type="bibr">102</xref>]. Furthermore, in the rhesus macaque model a single immunization of a different ZIKV prM/E encoding mRNA lipid nanoparticle vaccine demonstrated neutralizing antibody titers that were fifty times greater than those induced by a single immunization of a DNA vaccine and more than twice as high as those induced by two immunizations of a DNA vaccine measured using the same assay in the same laboratory [<xref rid="B103-viruses-09-00143" ref-type="bibr">103</xref>,<xref rid="B125-viruses-09-00143" ref-type="bibr">125</xref>]. These results indicate promise for RNA anti-ZIKV vaccine candidates. There is currently a Phase I clinical trial of an mRNA vaccine candidate underway (<xref ref-type="table" rid="viruses-09-00143-t001">Table 1</xref>) [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>].</p></sec><sec id="sec8dot4-viruses-09-00143"><title>8.4. Recombinant Viral Vector</title><p>In rhesus monkeys, a rhesus adenovirus serotype 52 (RhAd52) vector-based vaccine elicited ZIKV-specific neutralizing antibodies following a single immunization which demonstrated a substantial breadth of antibody responses against linear ZIKV E protein epitopes (peptide microarray assays) [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>]. Furthermore, this vaccine candidate protected against challenge with wt ZIKV as demonstrated by lack of detectable viral RNA in plasma [<xref rid="B79-viruses-09-00143" ref-type="bibr">79</xref>]. Very recently, a recombinant vesicular stomatitis virus (rVSV) anti-ZIKV vaccine was tested in mice and demonstrated maternal protective immunity in challenged newborn mice born to vaccinated mothers [<xref rid="B101-viruses-09-00143" ref-type="bibr">101</xref>]. Betancourt et al. investigated multiple rVSV expressing ZIKV E or prM/E constructs in mice and identified an attenuated VSV with mutated matrix protein expressing prM/E (VSVm-ZprME) that induced high neutralizing anti-ZIKV antibody titers as well as IFN-&#947; production by CD8+ T cells [<xref rid="B101-viruses-09-00143" ref-type="bibr">101</xref>]. Furthermore, in a neonatal mouse challenge model, seven-day-old mice born to VSVm-ZprME vaccinated mothers were partially protected against neurological manifestations of ZIKV infection following challenge [<xref rid="B101-viruses-09-00143" ref-type="bibr">101</xref>]. Additional recombinant viral-vectored anti-ZIKV vaccine candidates are in the pre-clinical stages of development [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>]. </p><p>Additional vaccine candidate platforms in pre-clinical studies include live-attenuated vaccines, recombinant subunit vaccines, peptide vaccines, and ZIKV exosome vaccines [<xref rid="B114-viruses-09-00143" ref-type="bibr">114</xref>].</p></sec></sec><sec id="sec9-viruses-09-00143"><title>9. Therapeutics</title><p>There are currently no drugs approved for the treatment of ZIKV-infection. The aim of drug development is primarily to reduce viral load, reduce symptoms, and protect the unborn fetus from neurological sequelae [<xref rid="B128-viruses-09-00143" ref-type="bibr">128</xref>]. Multiple studies have focused on &#8220;re-purposing&#8221; existing compounds for the treatment of ZIKV [<xref rid="B129-viruses-09-00143" ref-type="bibr">129</xref>,<xref rid="B130-viruses-09-00143" ref-type="bibr">130</xref>,<xref rid="B131-viruses-09-00143" ref-type="bibr">131</xref>,<xref rid="B132-viruses-09-00143" ref-type="bibr">132</xref>,<xref rid="B133-viruses-09-00143" ref-type="bibr">133</xref>,<xref rid="B134-viruses-09-00143" ref-type="bibr">134</xref>]. Zmurko et al. tested multiple compounds, including ribavirin and polymerase inhibitor 7-deaza-2&#8242;-C-methyladenosine (7DMA), to identify potential anti-ZIKV therapeutics [<xref rid="B134-viruses-09-00143" ref-type="bibr">134</xref>]. Of the compounds tested, 7DMA inhibited ZIKV replication in vitro, and, when administered for 10 consecutive days (beginning 1 h prior to infection), reduced viremia as well as delayed time to disease progression in ZIKV-infected AG129 mice [<xref rid="B134-viruses-09-00143" ref-type="bibr">134</xref>]. While 7DMA was well tolerated by the mice, there was only modest reduction in viremia and the initiation of treatment prior to infection is impractical in non-research settings. Rapid, high-throughput screening of drug/compound libraries has also been utilized in an attempt to identify compounds with in vitro anti-ZIKV activity [<xref rid="B129-viruses-09-00143" ref-type="bibr">129</xref>,<xref rid="B131-viruses-09-00143" ref-type="bibr">131</xref>]. In a large screen of 727 compounds using a high-throughput cell-based assay to screen for anti-ZIKV activity, ZIKV was found to be sensitive to pyrimidine synthesis inhibitors (e.g., brequinar) [<xref rid="B129-viruses-09-00143" ref-type="bibr">129</xref>]. Furthermore, Barrows et al. screened 774 FDA-approved drugs for anti-ZIKV activity and identified over 20 compounds, including mycophenolate mofetil, daptomycin, and sertraline, that reduced viral infection in vitro [<xref rid="B131-viruses-09-00143" ref-type="bibr">131</xref>]. In an even larger screen, ~6000 compounds, including approved drugs, clinical trial drug candidates, and pharmacologically active compounds, were tested to determine their ability to either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in neuronal cells [<xref rid="B133-viruses-09-00143" ref-type="bibr">133</xref>]. Of the compounds screened in this study, emricasan, a pan-caspase inhibitor, was the most potent anti-cell-death compound and it demonstrated neuroprotective activity for human neuronal progenitor cells, but did not suppress ZIKV replication [<xref rid="B133-viruses-09-00143" ref-type="bibr">133</xref>]. Additionally, several anti-malarial compounds were identified as having anti-DENV2 and anti-ZIKV properties using a cell-based cytotoxicity assay [<xref rid="B130-viruses-09-00143" ref-type="bibr">130</xref>]. Bullard-Feibelman et al. demonstrated that an FDA-approved hepatitis C virus (HCV) anti-viral, sofosbuvir, inhibited ZIKV replication and infection in tissue culture as well as protected mice from ZIKV-induced death [<xref rid="B132-viruses-09-00143" ref-type="bibr">132</xref>]. However, it is important to note that in this study mice were treated one day after inoculation with ZIKV, a time-line that is not practical in human infections. </p><p>Although anti-ZIKV therapeutic agents would likely be a welcome addition to the armamentarium, there are multiple challenges that face their development. Because clinical infection with ZIKV is typically mild, the primary populations for whom treatment would be indicated are pregnant women and those at increased risk for neurological complications, such as GBS. There are multiple ethical considerations in the development of therapeutics to be used during pregnancy. In general, pregnant women are excluded from clinical trials of new investigational compounds. In this setting, the inclusion of pregnant women would be warranted; however, the agent would need to be low risk to the mother, low risk to the fetus (not teratogenic), effective in preventing adverse fetal outcomes, and practical for use in resource-limited settings [<xref rid="B128-viruses-09-00143" ref-type="bibr">128</xref>]. </p></sec><sec id="sec10-viruses-09-00143"><title>10. Conclusions</title><p>ZIKV is a rapidly emerging virus with a complex clinical picture. To date, much progress has been made in understanding the epidemiology and pathogenesis as well as developing vaccines which are essential to addressing the spread of ZIKV. However, many questions remain and a sustained global effort is required to battle this public health threat. Among the major issues requiring attention are the need for: (a) an improved understanding of the epidemiology including the potential interaction of ZIKV infection with other flaviviral infections; (b) an improved understanding of the clinical risk factors and mechanisms of severe disease; (c) identification of immunological correlates of protection which may aid in the rapid development of vaccines; and (d) the development of additional animal models which faithfully recapitulate human disease to better understand ZIKV pathogenesis and facilitate the development of countermeasures. In sum, an improved understanding of the epidemiology, pathogenesis, clinical risk factors for severe manifestations, and immunological correlates of protection are critical in developing effective countermeasures against this pathogen, including vaccines and therapeutics.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported, in part, by the Robert Wood Johnson Foundation, Harold Amos Medical Faculty Development Program (73307) and the National Institute of Allergy and Infectious Diseases Cooperative Centers on Human Immunity (NIAID, U19 AI-110820).</p></ack><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-09-00143"><label>1.</label><element-citation publication-type="web"><article-title>WHO Situation Report 10 March 2017</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf?ua=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-04-02">(accessed on 2 April 2017)</date-in-citation></element-citation></ref><ref id="B2-viruses-09-00143"><label>2.</label><element-citation publication-type="web"><article-title>WHO Situation Report 24 November 2016</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/emergencies/zika-virus/situation-report/24-november-2016/en/">http://www.who.int/emergencies/zika-virus/situation-report/24-november-2016/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2016-12-27">(accessed on 27 December 2016)</date-in-citation></element-citation></ref><ref id="B3-viruses-09-00143"><label>3.</label><element-citation publication-type="web"><article-title>WHO Zika Situation Report 5 February 2016</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/204348/1/zikasitrep_5Feb2016_eng.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/204348/1/zikasitrep_5Feb2016_eng.pdf?ua=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-04-07">(accessed on 7 April 2017)</date-in-citation></element-citation></ref><ref id="B4-viruses-09-00143"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dick</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Kitchen</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Haddow</surname><given-names>A.J.</given-names></name></person-group><article-title>Zika virus. I. Isolations and serological specificity</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1952</year><volume>46</volume><fpage>509</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(52)90042-4</pub-id><pub-id pub-id-type="pmid">12995440</pub-id></element-citation></ref><ref id="B5-viruses-09-00143"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kool</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lanciotti</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Pretrick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marfel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holzbauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubray</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Zika virus outbreak on Yap Island, Federated States of Micronesia</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>2536</fpage><lpage>2543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805715</pub-id><pub-id pub-id-type="pmid">19516034</pub-id></element-citation></ref><ref id="B6-viruses-09-00143"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G.J.</given-names></name></person-group><article-title>Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses</article-title><source>Arch. Virol.</source><year>2007</year><volume>152</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s00705-006-0903-z</pub-id><pub-id pub-id-type="pmid">17195954</pub-id></element-citation></ref><ref id="B7-viruses-09-00143"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirohi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Klose</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>R.J.</given-names></name></person-group><article-title>The 3.8 A resolution cryo-EM structure of Zika virus</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>467</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1126/science.aaf5316</pub-id><pub-id pub-id-type="pmid">27033547</pub-id><pub-id pub-id-type="pmcid">PMC4845755</pub-id></element-citation></ref><ref id="B8-viruses-09-00143"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindenbach</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>C.M.</given-names></name></person-group><article-title>Molecular biology of flaviviruses</article-title><source>Adv. Virus Res.</source><year>2003</year><volume>59</volume><fpage>23</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">14696326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-3527(03)59002-9</pub-id></element-citation></ref><ref id="B9-viruses-09-00143"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Best</surname><given-names>S.M.</given-names></name></person-group><article-title>The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><pub-id pub-id-type="doi">10.1128/JVI.01970-16</pub-id><pub-id pub-id-type="pmid">27881649</pub-id><pub-id pub-id-type="pmcid">PMC5244349</pub-id></element-citation></ref><ref id="B10-viruses-09-00143"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaiah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arumugaswami</surname><given-names>V.</given-names></name></person-group><article-title>Comparative analysis of protein evolution in the genome of pre-epidemic and epidemic Zika virus</article-title><source>Infect. Genet. Evol.</source><year>2017</year><volume>51</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2017.03.012</pub-id><pub-id pub-id-type="pmid">28315476</pub-id></element-citation></ref><ref id="B11-viruses-09-00143"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Woolley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.M.</given-names></name></person-group><article-title>Zika virus: History, epidemiology, transmission, and clinical presentation</article-title><source>J. Neuroimmunol.</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.jneuroim.2017.03.001</pub-id><pub-id pub-id-type="pmid">28285789</pub-id></element-citation></ref><ref id="B12-viruses-09-00143"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao-Lormeau</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mons</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lastere</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vanhomwegen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dub</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baudouin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Teissier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larre</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>1531</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00562-6</pub-id><pub-id pub-id-type="pmid">26948433</pub-id><pub-id pub-id-type="pmcid">PMC5444521</pub-id></element-citation></ref><ref id="B13-viruses-09-00143"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oehler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Watrin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Larre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leparc-Goffart</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lastere</surname><given-names>S.</given-names></name><name name-style="western"><surname>Valour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Baudouin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mallet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Musso</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ghawche</surname><given-names>F.</given-names></name></person-group><article-title>Zika virus infection complicated by Guillain-Barre syndrome&#8212;Case report, French Polynesia, December 2013</article-title><source>Euro Surveill.</source><year>2014</year><volume>19</volume><fpage>20720</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES2014.19.9.20720</pub-id><pub-id pub-id-type="pmid">24626205</pub-id></element-citation></ref><ref id="B14-viruses-09-00143"><label>14.</label><element-citation publication-type="gov"><article-title>Zika Virus Cases in the US</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/zika/geo/united-states.html">https://www.cdc.gov/zika/geo/united-states.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-04-07">(accessed on 7 April 2017)</date-in-citation></element-citation></ref><ref id="B15-viruses-09-00143"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kindhauser</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>V.</given-names></name><name name-style="western"><surname>Santhana</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Dye</surname><given-names>C.</given-names></name></person-group><article-title>Zika: The origin and spread of a mosquito-borne virus</article-title><source>Bull. World Health Organ.</source><year>2016</year><volume>94</volume><fpage>675</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.2471/BLT.16.171082</pub-id><pub-id pub-id-type="pmid">27708473</pub-id><pub-id pub-id-type="pmcid">PMC5034643</pub-id></element-citation></ref><ref id="B16-viruses-09-00143"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S.K.</given-names></name></person-group><article-title>Zika Virus: Transmission, Detection, Control, and Prevention</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.00110</pub-id><pub-id pub-id-type="pmid">28217114</pub-id><pub-id pub-id-type="pmcid">PMC5290000</pub-id></element-citation></ref><ref id="B17-viruses-09-00143"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Ortenzio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Matheron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Piorkowski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maquart</surname><given-names>M.</given-names></name><name name-style="western"><surname>Descamps</surname><given-names>D.</given-names></name><name name-style="western"><surname>Damond</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leparc-Goffart</surname><given-names>I.</given-names></name></person-group><article-title>Evidence of Sexual Transmission of Zika Virus</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>374</volume><fpage>2195</fpage><lpage>2198</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1604449</pub-id><pub-id pub-id-type="pmid">27074370</pub-id></element-citation></ref><ref id="B18-viruses-09-00143"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foy</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Kobylinski</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Chilson Foy</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Blitvich</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Travassos da Rosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haddow</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Lanciotti</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Tesh</surname><given-names>R.B.</given-names></name></person-group><article-title>Probable non-vector-borne transmission of Zika virus, Colorado, USA</article-title><source>Emerg. Infect. Dis.</source><year>2011</year><volume>17</volume><fpage>880</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.3201/eid1705.101939</pub-id><pub-id pub-id-type="pmid">21529401</pub-id><pub-id pub-id-type="pmcid">PMC3321795</pub-id></element-citation></ref><ref id="B19-viruses-09-00143"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cadar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schlaphof</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neddersen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmidt-Chanasit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tappe</surname><given-names>D.</given-names></name></person-group><article-title>Sexual transmission of Zika virus in Germany, April 2016</article-title><source>Euro Surveill.</source><year>2016</year><volume>21</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2016.21.23.30252</pub-id><pub-id pub-id-type="pmid">27311329</pub-id></element-citation></ref><ref id="B20-viruses-09-00143"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freour</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mirallie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Splingart</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barriere</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maquart</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leparc-Goffart</surname><given-names>I.</given-names></name></person-group><article-title>Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016</article-title><source>Euro Surveill.</source><year>2016</year><volume>21</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2016.21.23.30254</pub-id><pub-id pub-id-type="pmid">27311680</pub-id></element-citation></ref><ref id="B21-viruses-09-00143"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>N.L.</given-names></name></person-group><article-title>Prospects for a Zika Virus Vaccine</article-title><source>Immunity</source><year>2017</year><volume>46</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.005</pub-id><pub-id pub-id-type="pmid">28228277</pub-id><pub-id pub-id-type="pmcid">PMC5357134</pub-id></element-citation></ref><ref id="B22-viruses-09-00143"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waggoner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Gresh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ballesteros</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tellez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Soda</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balmaseda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>1584</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw589</pub-id><pub-id pub-id-type="pmid">27578819</pub-id><pub-id pub-id-type="pmcid">PMC5146717</pub-id></element-citation></ref><ref id="B23-viruses-09-00143"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grossi-Soyster</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>LaBeaud</surname><given-names>A.D.</given-names></name></person-group><article-title>Clinical aspects of Zika virus</article-title><source>Curr. Opin. Pediatr.</source><year>2016</year><pub-id pub-id-type="doi">10.1097/MOP.0000000000000449</pub-id><pub-id pub-id-type="pmid">27870688</pub-id></element-citation></ref><ref id="B24-viruses-09-00143"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brasil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Calvet</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Siqueira</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wakimoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Sequeira</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Nobre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quintana Mde</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mendonca</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lupi</surname><given-names>O.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>R.V.</given-names></name><etal/></person-group><article-title>Zika Virus Outbreak in Rio de Janeiro, Brazil: Clinical Characterization, Epidemiological and Virological Aspects</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004636</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004636</pub-id><pub-id pub-id-type="pmid">27070912</pub-id><pub-id pub-id-type="pmcid">PMC4829157</pub-id></element-citation></ref><ref id="B25-viruses-09-00143"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calvet</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Sequeira</surname><given-names>P.C.</given-names></name></person-group><article-title>Zika virus infection: Epidemiology, clinical manifestations and diagnosis</article-title><source>Curr. Opin. Infect. Dis.</source><year>2016</year><volume>29</volume><fpage>459</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000301</pub-id><pub-id pub-id-type="pmid">27496713</pub-id></element-citation></ref><ref id="B26-viruses-09-00143"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arzuza-Ortega</surname><given-names>L.</given-names></name><name name-style="western"><surname>Polo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez-Tatis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lopez-Garcia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Parra</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pardo-Herrera</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Rico-Turca</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Villamil-Gomez</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name></person-group><article-title>Fatal Sickle Cell Disease and Zika Virus Infection in Girl from Colombia</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>925</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.3201/eid2205.151934</pub-id><pub-id pub-id-type="pmid">27089120</pub-id><pub-id pub-id-type="pmcid">PMC4861530</pub-id></element-citation></ref><ref id="B27-viruses-09-00143"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azevedo</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Martins Filho</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Caldas</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>F.C.</given-names></name><etal/></person-group><article-title>Zika virus epidemic in Brazil. I. Fatal disease in adults: Clinical and laboratorial aspects</article-title><source>J. Clin. Virol.</source><year>2016</year><volume>85</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2016.10.024</pub-id><pub-id pub-id-type="pmid">27835759</pub-id><pub-id pub-id-type="pmcid">PMC5233712</pub-id></element-citation></ref><ref id="B28-viruses-09-00143"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dirlikov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ryff</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Torres-Aponte</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Perez-Padilla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Munoz-Jordan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caraballo</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Segarra</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Malave</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Update: Ongoing Zika Virus Transmission&#8212;Puerto Rico, 1 November 2015&#8211;14 April 2016</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>451</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6517e2</pub-id><pub-id pub-id-type="pmid">27149205</pub-id></element-citation></ref><ref id="B29-viruses-09-00143"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarmiento-Ospina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vasquez-Serna</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jimenez-Canizales</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Villamil-Gomez</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name></person-group><article-title>Zika virus associated deaths in Colombia</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><fpage>523</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)30006-8</pub-id><pub-id pub-id-type="pmid">27068488</pub-id></element-citation></ref><ref id="B30-viruses-09-00143"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soares</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Brasil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carrera</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sequeira</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Filippis</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Theophilo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ellul</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>T.</given-names></name></person-group><article-title>Fatal encephalitis associated with Zika virus infection in an adult</article-title><source>J. Clin. Virol.</source><year>2016</year><volume>83</volume><fpage>63</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2016.08.297</pub-id><pub-id pub-id-type="pmid">27598870</pub-id></element-citation></ref><ref id="B31-viruses-09-00143"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swaminathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schlaberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Couturier</surname><given-names>M.R.</given-names></name></person-group><article-title>Fatal Zika Virus Infection with Secondary Nonsexual Transmission</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1907</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1610613</pub-id><pub-id pub-id-type="pmid">27681699</pub-id><pub-id pub-id-type="pmcid">PMC5267509</pub-id></element-citation></ref><ref id="B32-viruses-09-00143"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brasil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sequeira</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Zogbi</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Calvet</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Siqueira</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>de Mendonca</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>de Filippis</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Guillain-Barre syndrome associated with Zika virus infection</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>1482</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30058-7</pub-id><pub-id pub-id-type="pmid">27115821</pub-id></element-citation></ref><ref id="B33-viruses-09-00143"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>H.P.</given-names></name></person-group><article-title>Guillain-Barre syndrome</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>366</volume><fpage>2294</fpage><lpage>2304</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1114525</pub-id><pub-id pub-id-type="pmid">22694000</pub-id></element-citation></ref><ref id="B34-viruses-09-00143"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandhu</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>W.</given-names></name><name name-style="western"><surname>MaCurdy</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Franks</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Avagyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kelman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Worrall</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.</given-names></name></person-group><article-title>Near real-time surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>2986</fpage><lpage>2992</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.087</pub-id><pub-id pub-id-type="pmid">28449973</pub-id></element-citation></ref><ref id="B35-viruses-09-00143"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carteaux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maquart</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bedet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Contou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brugieres</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cleret de Langavant</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Broucker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brun-Buisson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leparc-Goffart</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Zika Virus Associated with Meningoencephalitis</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>374</volume><fpage>1595</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1602964</pub-id><pub-id pub-id-type="pmid">26958738</pub-id></element-citation></ref><ref id="B36-viruses-09-00143"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mecharles</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Poullain</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Deschamps</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mathon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Landais</surname><given-names>A.</given-names></name><name name-style="western"><surname>Breurec</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lannuzel</surname><given-names>A.</given-names></name></person-group><article-title>Acute myelitis due to Zika virus infection</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>1481</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00644-9</pub-id><pub-id pub-id-type="pmid">26946926</pub-id></element-citation></ref><ref id="B37-viruses-09-00143"><label>37.</label><element-citation publication-type="web"><article-title>Epidemiological Alert Increase of Microcephaly in the Northeast of Brazil</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.paho.org/hq/index.php?option=com_docman&amp;task=doc_view&amp;Itemid=270&amp;gid=32285&amp;lang=en">http://www.paho.org/hq/index.php?option=com_docman&amp;task=doc_view&amp;Itemid=270&amp;gid=32285&amp;lang=en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-04-07">(accessed on 7 April 2017)</date-in-citation></element-citation></ref><ref id="B38-viruses-09-00143"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boeuf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Drummer</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Scoullar</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Beeson</surname><given-names>J.G.</given-names></name></person-group><article-title>The global threat of Zika virus to pregnancy: Epidemiology, clinical perspectives, mechanisms, and impact</article-title><source>BMC Med.</source><year>2016</year><volume>14</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-016-0660-0</pub-id><pub-id pub-id-type="pmid">27487767</pub-id><pub-id pub-id-type="pmcid">PMC4973112</pub-id></element-citation></ref><ref id="B39-viruses-09-00143"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Miranda-Filho</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sobral</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>de Alencar</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>M.L.</given-names></name></person-group><article-title>Sleep EEG patterns in infants with congenital Zika virus syndrome</article-title><source>Clin. Neurophysiol.</source><year>2016</year><volume>128</volume><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2016.11.004</pub-id><pub-id pub-id-type="pmid">27923187</pub-id></element-citation></ref><ref id="B40-viruses-09-00143"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cauchemez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Besnard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bompard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dub</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guillemette-Artur</surname><given-names>P.</given-names></name><name name-style="western"><surname>Eyrolle-Guignot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salje</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Kerkhove</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Abadie</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garel</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Association between Zika virus and microcephaly in French Polynesia, 2013&#8211;2015: A retrospective study</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>2125</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00651-6</pub-id><pub-id pub-id-type="pmid">26993883</pub-id><pub-id pub-id-type="pmcid">PMC4909533</pub-id></element-citation></ref><ref id="B41-viruses-09-00143"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Duran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gulmezoglu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oladapo</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Perea</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramon-Pardo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rollins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>S.</given-names></name></person-group><article-title>Defining the syndrome associated with congenital Zika virus infection</article-title><source>Bull. World Health Organ.</source><year>2016</year><volume>94</volume><fpage>406A</fpage><pub-id pub-id-type="doi">10.2471/BLT.16.176990</pub-id><pub-id pub-id-type="pmid">27274588</pub-id><pub-id pub-id-type="pmcid">PMC4890216</pub-id></element-citation></ref><ref id="B42-viruses-09-00143"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Paula Freitas</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Oliveira Dias</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Prazeres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sacramento</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Belfort</surname><given-names>R.</given-names></name></person-group><article-title>Ocular Findings in Infants With Microcephaly Associated With Presumed Zika Virus Congenital Infection in Salvador, Brazil</article-title><source>JAMA Ophthalmol.</source><year>2016</year><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2016.0267</pub-id><pub-id pub-id-type="pmid">26865554</pub-id><pub-id pub-id-type="pmcid">PMC5444996</pub-id></element-citation></ref><ref id="B43-viruses-09-00143"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Paula Freitas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Khouri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mayoral</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Belfort</surname><given-names>R.</given-names></name></person-group><article-title>Glaucoma and Congenital Zika Syndrome</article-title><source>Ophthalmology</source><year>2016</year><pub-id pub-id-type="doi">10.1016/j.ophtha.2016.10.004</pub-id><pub-id pub-id-type="pmid">27914834</pub-id></element-citation></ref><ref id="B44-viruses-09-00143"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleber de Oliveira</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cortez-Escalante</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>do Carmo</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Araujo de Franca</surname><given-names>G.V.</given-names></name></person-group><article-title>Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy&#8212;Brazil, 2015</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>242</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6509e2</pub-id><pub-id pub-id-type="pmid">26963593</pub-id></element-citation></ref><ref id="B45-viruses-09-00143"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>C.</given-names></name><name name-style="western"><surname>Faber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>K.</given-names></name></person-group><article-title>Causal or not: Applying the Bradford Hill aspects of evidence to the association between Zika virus and microcephaly</article-title><source>EMBO Mol. Med.</source><year>2016</year><volume>8</volume><fpage>305</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.15252/emmm.201506058</pub-id><pub-id pub-id-type="pmid">26976611</pub-id><pub-id pub-id-type="pmcid">PMC4818755</pub-id></element-citation></ref><ref id="B46-viruses-09-00143"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Honein</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>L.R.</given-names></name></person-group><article-title>Zika Virus and Birth Defects&#8212;Reviewing the Evidence for Causality</article-title><source>N. Engl. J. Med.</source><year>2016</year><pub-id pub-id-type="doi">10.1056/NEJMsr1604338</pub-id><pub-id pub-id-type="pmid">27074377</pub-id></element-citation></ref><ref id="B47-viruses-09-00143"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martines</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Oliveira Ramos</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Davi</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Iglezias</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Kanamura</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Keating</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silva-Flannery</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muehlenbachs</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pathology of congenital Zika syndrome in Brazil: A case series</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>898</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30883-2</pub-id><pub-id pub-id-type="pmid">27372395</pub-id></element-citation></ref><ref id="B48-viruses-09-00143"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mlakar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tul</surname><given-names>N.</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poljsak-Prijatelj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mraz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kolenc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Resman Rus</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vesnaver Vipotnik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fabjan Vodusek</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Zika Virus Associated with Microcephaly</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>374</volume><fpage>951</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1600651</pub-id><pub-id pub-id-type="pmid">26862926</pub-id></element-citation></ref><ref id="B49-viruses-09-00143"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hammack</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth</article-title><source>Cell Stem Cell</source><year>2016</year><volume>18</volume><fpage>587</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.02.016</pub-id><pub-id pub-id-type="pmid">26952870</pub-id><pub-id pub-id-type="pmcid">PMC5299540</pub-id></element-citation></ref><ref id="B50-viruses-09-00143"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quicke</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Neal</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Rajakumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rimawi</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Zika Virus Infects Human Placental Macrophages</article-title><source>Cell Host Microbe</source><year>2016</year><volume>20</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.05.015</pub-id><pub-id pub-id-type="pmid">27247001</pub-id><pub-id pub-id-type="pmcid">PMC5166429</pub-id></element-citation></ref><ref id="B51-viruses-09-00143"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams Waldorf</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Stencel-Baerenwald</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Studholme</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boldenow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vornhagen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baldessari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dighe</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Merillat</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate</article-title><source>Nat. Med.</source><year>2016</year><volume>22</volume><fpage>1256</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1038/nm.4193</pub-id><pub-id pub-id-type="pmid">27618651</pub-id><pub-id pub-id-type="pmcid">PMC5365281</pub-id></element-citation></ref><ref id="B52-viruses-09-00143"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cugola</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Guimaraes</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Benazzato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pignatari</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The Brazilian Zika virus strain causes birth defects in experimental models</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/nature18296</pub-id><pub-id pub-id-type="pmid">27279226</pub-id><pub-id pub-id-type="pmcid">PMC4902174</pub-id></element-citation></ref><ref id="B53-viruses-09-00143"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name></person-group><article-title>Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice</article-title><source>Cell Stem Cell</source><year>2016</year><volume>19</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.04.017</pub-id><pub-id pub-id-type="pmid">27179424</pub-id></element-citation></ref><ref id="B54-viruses-09-00143"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Govero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Garber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Noll</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>K.K.</given-names></name><etal/></person-group><article-title>Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.008</pub-id><pub-id pub-id-type="pmid">27180225</pub-id><pub-id pub-id-type="pmcid">PMC4874881</pub-id></element-citation></ref><ref id="B55-viruses-09-00143"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name></person-group><article-title>Animal Models of Zika Virus Infection, Pathogenesis, and Immunity</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><pub-id pub-id-type="doi">10.1128/JVI.00009-17</pub-id><pub-id pub-id-type="pmid">28148798</pub-id><pub-id pub-id-type="pmcid">PMC5375682</pub-id></element-citation></ref><ref id="B56-viruses-09-00143"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dick</surname><given-names>G.W.</given-names></name></person-group><article-title>Zika virus. II. Pathogenicity and physical properties</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1952</year><volume>46</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(52)90043-6</pub-id><pub-id pub-id-type="pmid">12995441</pub-id></element-citation></ref><ref id="B57-viruses-09-00143"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.G.</given-names></name></person-group><article-title>Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice</article-title><source>Cell Res.</source><year>2016</year><volume>26</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.58</pub-id><pub-id pub-id-type="pmid">27174054</pub-id><pub-id pub-id-type="pmcid">PMC4897185</pub-id></element-citation></ref><ref id="B58-viruses-09-00143"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elong Ngono</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vizcarra</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Sheets</surname><given-names>N.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Shresta</surname><given-names>S.</given-names></name></person-group><article-title>Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice</article-title><source>Cell Host Microbe</source><year>2017</year><volume>21</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.12.010</pub-id><pub-id pub-id-type="pmid">28081442</pub-id><pub-id pub-id-type="pmcid">PMC5234855</pub-id></element-citation></ref><ref id="B59-viruses-09-00143"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazear</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Govero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Platt</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name></person-group><article-title>A Mouse Model of Zika Virus Pathogenesis</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>720</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.03.010</pub-id><pub-id pub-id-type="pmid">27066744</pub-id><pub-id pub-id-type="pmcid">PMC4866885</pub-id></element-citation></ref><ref id="B60-viruses-09-00143"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aliota</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Caine</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>E.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>J.E.</given-names></name></person-group><article-title>Characterization of Lethal Zika Virus Infection in AG129 Mice</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004682</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004682</pub-id><pub-id pub-id-type="pmid">27093158</pub-id><pub-id pub-id-type="pmcid">PMC4836712</pub-id></element-citation></ref><ref id="B61-viruses-09-00143"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowall</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>G.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bosworth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonney</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Kitchen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hewson</surname><given-names>R.</given-names></name></person-group><article-title>A Susceptible Mouse Model for Zika Virus Infection</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004658</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004658</pub-id><pub-id pub-id-type="pmid">27149521</pub-id><pub-id pub-id-type="pmcid">PMC4858159</pub-id></element-citation></ref><ref id="B62-viruses-09-00143"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tesh</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Muruato</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Auguste</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Langsjoen</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Paessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vasilakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Characterization of a Novel Murine Model to Study Zika Virus</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2016</year><volume>94</volume><fpage>1362</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0111</pub-id><pub-id pub-id-type="pmid">27022155</pub-id><pub-id pub-id-type="pmcid">PMC4889758</pub-id></element-citation></ref><ref id="B63-viruses-09-00143"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Tee</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons</article-title><source>EBioMedicine</source><year>2016</year><volume>14</volume><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.11.017</pub-id><pub-id pub-id-type="pmid">27884655</pub-id><pub-id pub-id-type="pmcid">PMC5161441</pub-id></element-citation></ref><ref id="B64-viruses-09-00143"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yockey</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Varela</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rakib</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khoury-Hanold</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Szigeti-Buck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Van den Pol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lindenbach</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>T.L.</given-names></name><etal/></person-group><article-title>Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain Infection</article-title><source>Cell</source><year>2016</year><volume>166</volume><fpage>1247</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.004</pub-id><pub-id pub-id-type="pmid">27565347</pub-id><pub-id pub-id-type="pmcid">PMC5006689</pub-id></element-citation></ref><ref id="B65-viruses-09-00143"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arck</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Hecher</surname><given-names>K.</given-names></name></person-group><article-title>Fetomaternal immune cross-talk and its consequences for maternal and offspring&#8217;s health</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>548</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/nm.3160</pub-id><pub-id pub-id-type="pmid">23652115</pub-id></element-citation></ref><ref id="B66-viruses-09-00143"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mysorekar</surname><given-names>I.U.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name></person-group><article-title>Modeling Zika Virus Infection in Pregnancy</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1056/NEJMcibr1605445</pub-id><pub-id pub-id-type="pmid">27433842</pub-id></element-citation></ref><ref id="B67-viruses-09-00143"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudley</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Aliota</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Weiler</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lehrer-Brey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Weisgrau</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Mohns</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Breitbach</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>A <italic toggle="yes">Rhesus macaque</italic> model of Asian-lineage Zika virus infection</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12204</fpage><pub-id pub-id-type="doi">10.1038/ncomms12204</pub-id><pub-id pub-id-type="pmid">27352279</pub-id><pub-id pub-id-type="pmcid">PMC4931337</pub-id></element-citation></ref><ref id="B68-viruses-09-00143"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osuna</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Deleage</surname><given-names>C.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Omange</surname><given-names>R.</given-names></name><name name-style="western"><surname>Best</surname><given-names>K.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hraber</surname><given-names>P.T.</given-names></name><etal/></person-group><article-title>Zika viral dynamics and shedding in rhesus and cynomolgus macaques</article-title><source>Nat. Med.</source><year>2016</year><volume>22</volume><fpage>1448</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1038/nm.4206</pub-id><pub-id pub-id-type="pmid">27694931</pub-id><pub-id pub-id-type="pmcid">PMC5293594</pub-id></element-citation></ref><ref id="B69-viruses-09-00143"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffey</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Pesavento</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Keesler</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Singapuri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bliss-Moreau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cruzen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Christe</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>Zika Virus Tissue and Blood Compartmentalization in Acute Infection of <italic toggle="yes">Rhesus macaques</italic></article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0171148</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0171148</pub-id><pub-id pub-id-type="pmid">28141843</pub-id><pub-id pub-id-type="pmcid">PMC5283740</pub-id></element-citation></ref><ref id="B70-viruses-09-00143"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Chevillotte</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>C.M.</given-names></name></person-group><article-title>Interferon-stimulated genes: A complex web of host defenses</article-title><source>Annu. Rev. Immunol.</source><year>2014</year><volume>32</volume><fpage>513</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id><pub-id pub-id-type="pmid">24555472</pub-id><pub-id pub-id-type="pmcid">PMC4313732</pub-id></element-citation></ref><ref id="B71-viruses-09-00143"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lennemann</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bramley</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Morosky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>E.T.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Cherry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sadovsky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Coyne</surname><given-names>C.B.</given-names></name></person-group><article-title>Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.03.008</pub-id><pub-id pub-id-type="pmid">27066743</pub-id><pub-id pub-id-type="pmcid">PMC4866896</pub-id></element-citation></ref><ref id="B72-viruses-09-00143"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Versteeg</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Viral tricks to grid-lock the type I interferon system</article-title><source>Curr. Opin. Microbiol.</source><year>2010</year><volume>13</volume><fpage>508</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2010.05.009</pub-id><pub-id pub-id-type="pmid">20538505</pub-id><pub-id pub-id-type="pmcid">PMC2920345</pub-id></element-citation></ref><ref id="B73-viruses-09-00143"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ponia</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balasubramaniam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Miorin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sourisseau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Sanchez-Seco</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Best</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>882</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.05.009</pub-id><pub-id pub-id-type="pmid">27212660</pub-id><pub-id pub-id-type="pmcid">PMC4900918</pub-id></element-citation></ref><ref id="B74-viruses-09-00143"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotenko</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baurin</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Lewis-Antes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dickensheets</surname><given-names>H.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.P.</given-names></name></person-group><article-title>IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex</article-title><source>Nat. Immunol.</source><year>2003</year><volume>4</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/ni875</pub-id><pub-id pub-id-type="pmid">12483210</pub-id></element-citation></ref><ref id="B75-viruses-09-00143"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woodruff</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Trapecar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ezaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borbet</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanjabi</surname><given-names>S.</given-names></name></person-group><article-title>Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication</article-title><source>J. Exp. Med.</source><year>2016</year><volume>213</volume><fpage>2913</fpage><lpage>2929</lpage><pub-id pub-id-type="doi">10.1084/jem.20161289</pub-id><pub-id pub-id-type="pmid">27852793</pub-id><pub-id pub-id-type="pmcid">PMC5154948</pub-id></element-citation></ref><ref id="B76-viruses-09-00143"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sapparapu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bombardi</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice</article-title><source>Nature</source><year>2016</year><volume>540</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature20564</pub-id><pub-id pub-id-type="pmid">27819683</pub-id><pub-id pub-id-type="pmcid">PMC5583716</pub-id></element-citation></ref><ref id="B77-viruses-09-00143"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stettler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Beltramello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cassotta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanzetta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Minola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jaconi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mele</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection</article-title><source>Science</source><year>2016</year><volume>353</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1126/science.aaf8505</pub-id><pub-id pub-id-type="pmid">27417494</pub-id></element-citation></ref><ref id="B78-viruses-09-00143"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanstrom</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Young</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gallichotte</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Widman</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus</article-title><source>MBio</source><year>2016</year><volume>7</volume><pub-id pub-id-type="doi">10.1128/mBio.01123-16</pub-id><pub-id pub-id-type="pmid">27435464</pub-id><pub-id pub-id-type="pmcid">PMC4958264</pub-id></element-citation></ref><ref id="B79-viruses-09-00143"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbink</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larocca</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>De La Barrera</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Bricault</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Moseley</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirilova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ng'ang'a</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nanayakkara</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys</article-title><source>Science</source><year>2016</year><volume>353</volume><fpage>1129</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1126/science.aah6157</pub-id><pub-id pub-id-type="pmid">27492477</pub-id><pub-id pub-id-type="pmcid">PMC5237380</pub-id></element-citation></ref><ref id="B80-viruses-09-00143"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kudchodkar</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Duperret</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Keaton</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.</given-names></name><etal/></person-group><article-title>In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine</article-title><source>Npj Vaccines</source><year>2016</year><volume>1</volume><pub-id pub-id-type="doi">10.1038/npjvaccines.2016.21</pub-id><pub-id pub-id-type="pmcid">PMC5707885</pub-id><pub-id pub-id-type="pmid">29263859</pub-id></element-citation></ref><ref id="B81-viruses-09-00143"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Madrid</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Porterfield</surname><given-names>J.S.</given-names></name></person-group><article-title>The flaviviruses (group B arboviruses): A cross-neutralization study</article-title><source>J. Gen. Virol.</source><year>1974</year><volume>23</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-23-1-91</pub-id><pub-id pub-id-type="pmid">4833603</pub-id></element-citation></ref><ref id="B82-viruses-09-00143"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Morens</surname><given-names>D.M.</given-names></name></person-group><article-title>Zika Virus in the Americas&#8212;Yet Another Arbovirus Threat</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>374</volume><fpage>601</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1600297</pub-id><pub-id pub-id-type="pmid">26761185</pub-id></element-citation></ref><ref id="B83-viruses-09-00143"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barba-Spaeth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rouvinski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaney</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Medits</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simon-Loriere</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sakuntabhai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cao-Lormeau</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Haouz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Structural basis of potent Zika-dengue virus antibody cross-neutralization</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nature18938</pub-id><pub-id pub-id-type="pmid">27338953</pub-id></element-citation></ref><ref id="B84-viruses-09-00143"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wongwiwat</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rouvinski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barba-Spaeth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Duangchinda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakuntabhai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cao-Lormeau</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Malasit</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>F.A.</given-names></name><etal/></person-group><article-title>Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus</article-title><source>Nat. Immunol.</source><year>2016</year><volume>17</volume><fpage>1102</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/ni.3515</pub-id><pub-id pub-id-type="pmid">27339099</pub-id><pub-id pub-id-type="pmcid">PMC4994874</pub-id></element-citation></ref><ref id="B85-viruses-09-00143"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>S.C.</given-names></name></person-group><article-title>Immunogenic cross-talk between dengue and Zika viruses</article-title><source>Nat. Immunol.</source><year>2016</year><volume>17</volume><fpage>1010</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/ni.3539</pub-id><pub-id pub-id-type="pmid">27540984</pub-id></element-citation></ref><ref id="B86-viruses-09-00143"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priyamvada</surname><given-names>L.</given-names></name><name name-style="western"><surname>Quicke</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Onlamoon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sewatanon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Edupuganti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pattanapanyasat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chokephaibulkit</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>7852</fpage><lpage>7857</lpage><pub-id pub-id-type="doi">10.1073/pnas.1607931113</pub-id><pub-id pub-id-type="pmid">27354515</pub-id><pub-id pub-id-type="pmcid">PMC4948328</pub-id></element-citation></ref><ref id="B87-viruses-09-00143"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>S.B.</given-names></name></person-group><article-title>Neutralization and antibody-dependent enhancement of dengue viruses</article-title><source>Adv. Virus Res.</source><year>2003</year><volume>60</volume><fpage>421</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">14689700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-3527(03)60011-4</pub-id></element-citation></ref><ref id="B88-viruses-09-00143"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>S.B.</given-names></name></person-group><article-title>Antibodies determine virulence in dengue</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2009</year><volume>1171</volume><fpage>E48</fpage><lpage>E56</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05052.x</pub-id><pub-id pub-id-type="pmid">19751402</pub-id></element-citation></ref><ref id="B89-viruses-09-00143"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kliks</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Nisalak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>D.S.</given-names></name></person-group><article-title>Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1989</year><volume>40</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1989.40.444</pub-id><pub-id pub-id-type="pmid">2712199</pub-id></element-citation></ref><ref id="B90-viruses-09-00143"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahala</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.M.</given-names></name></person-group><article-title>The human antibody response to dengue virus infection</article-title><source>Viruses</source><year>2011</year><volume>3</volume><fpage>2374</fpage><lpage>2395</lpage><pub-id pub-id-type="doi">10.3390/v3122374</pub-id><pub-id pub-id-type="pmid">22355444</pub-id><pub-id pub-id-type="pmcid">PMC3280510</pub-id></element-citation></ref><ref id="B91-viruses-09-00143"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duangchinda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vasanawathana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Limpitikul</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tangthawornchaikul</surname><given-names>N.</given-names></name><name name-style="western"><surname>Malasit</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mongkolsapaya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Screaton</surname><given-names>G.</given-names></name></person-group><article-title>Immunodominant T-cell responses to dengue virus NS3 are associated with DHF</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>16922</fpage><lpage>16927</lpage><pub-id pub-id-type="doi">10.1073/pnas.1010867107</pub-id><pub-id pub-id-type="pmid">20837518</pub-id><pub-id pub-id-type="pmcid">PMC2947904</pub-id></element-citation></ref><ref id="B92-viruses-09-00143"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M.Q.</given-names></name></person-group><article-title>CD4+ and CD8+ T-cell immunity to Dengue&#8212;Lessons for the study of Zika virus</article-title><source>Immunology</source><year>2016</year><pub-id pub-id-type="doi">10.1111/imm.12681</pub-id><pub-id pub-id-type="pmid">27763656</pub-id><pub-id pub-id-type="pmcid">PMC5214511</pub-id></element-citation></ref><ref id="B93-viruses-09-00143"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Dung</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Thao le</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Dung</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Hien</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Rowland-Jones</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>J.</given-names></name></person-group><article-title>Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>5665</fpage><lpage>5675</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.9.5665-5675.2005</pub-id><pub-id pub-id-type="pmid">15827181</pub-id><pub-id pub-id-type="pmcid">PMC1082776</pub-id></element-citation></ref><ref id="B94-viruses-09-00143"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Angelo</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shresta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>11383</fpage><lpage>11394</lpage><pub-id pub-id-type="doi">10.1128/JVI.01108-14</pub-id><pub-id pub-id-type="pmid">25056881</pub-id><pub-id pub-id-type="pmcid">PMC4178794</pub-id></element-citation></ref><ref id="B95-viruses-09-00143"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>T-cell immunity to infection with dengue virus in humans</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00093</pub-id><pub-id pub-id-type="pmid">24639680</pub-id><pub-id pub-id-type="pmcid">PMC3945531</pub-id></element-citation></ref><ref id="B96-viruses-09-00143"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akondy</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Monson</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Edupuganti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teuwen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Quyyumi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Del Rio</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>7919</fpage><lpage>7930</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803903</pub-id><pub-id pub-id-type="pmid">19933869</pub-id><pub-id pub-id-type="pmcid">PMC3374958</pub-id></element-citation></ref><ref id="B97-viruses-09-00143"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Janosko</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Josleyn</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M.R.</given-names></name></person-group><article-title>Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004709</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004709</pub-id><pub-id pub-id-type="pmid">27191161</pub-id><pub-id pub-id-type="pmcid">PMC4871483</pub-id></element-citation></ref><ref id="B98-viruses-09-00143"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Akondy</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Glidewell</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Albott</surname><given-names>S.</given-names></name><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murali-Krishna</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mahar</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Edupuganti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines</article-title><source>Immunity</source><year>2008</year><volume>28</volume><fpage>710</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.020</pub-id><pub-id pub-id-type="pmid">18468462</pub-id></element-citation></ref><ref id="B99-viruses-09-00143"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Uyangaa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Eo</surname><given-names>S.K.</given-names></name></person-group><article-title>CCR5 ameliorates Japanese encephalitis via dictating the equilibrium of regulatory CD4(+)Foxp3(+) T and IL-17(+)CD4(+) Th17 cells</article-title><source>J. Neuroinflamm.</source><year>2016</year><volume>13</volume><fpage>223</fpage><pub-id pub-id-type="doi">10.1186/s12974-016-0656-x</pub-id><pub-id pub-id-type="pmid">27439902</pub-id><pub-id pub-id-type="pmcid">PMC5050958</pub-id></element-citation></ref><ref id="B100-viruses-09-00143"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>M.J.</given-names></name></person-group><article-title>CD8 and CD4 T cells in West Nile virus immunity and pathogenesis</article-title><source>Viruses</source><year>2013</year><volume>5</volume><fpage>2573</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.3390/v5102573</pub-id><pub-id pub-id-type="pmid">24153060</pub-id><pub-id pub-id-type="pmcid">PMC3814605</pub-id></element-citation></ref><ref id="B101-viruses-09-00143"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Betancourt</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Queiroz</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity</article-title><source>J. Immunol.</source><year>2017</year><volume>198</volume><fpage>3023</fpage><lpage>3028</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1602180</pub-id><pub-id pub-id-type="pmid">28289159</pub-id></element-citation></ref><ref id="B102-viruses-09-00143"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahal</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Woodham</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Ploegh</surname><given-names>H.L.</given-names></name></person-group><article-title>An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>252</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-00193-w</pub-id><pub-id pub-id-type="pmid">28325910</pub-id><pub-id pub-id-type="pmcid">PMC5427874</pub-id></element-citation></ref><ref id="B103-viruses-09-00143"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Pelc</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H.</given-names></name><name name-style="western"><surname>DeMaso</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Scearce</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination</article-title><source>Nature</source><year>2017</year><volume>543</volume><fpage>248</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nature21428</pub-id><pub-id pub-id-type="pmid">28151488</pub-id><pub-id pub-id-type="pmcid">PMC5344708</pub-id></element-citation></ref><ref id="B104-viruses-09-00143"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charrel</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Leparc-Goffart</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pas</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.</given-names></name></person-group><article-title>Background review for diagnostic test development for Zika virus infection</article-title><source>Bull. World Health Organ.</source><year>2016</year><volume>94</volume><fpage>574D</fpage><lpage>584D</lpage><pub-id pub-id-type="doi">10.2471/BLT.16.171207</pub-id><pub-id pub-id-type="pmid">27516635</pub-id><pub-id pub-id-type="pmcid">PMC4969995</pub-id></element-citation></ref><ref id="B105-viruses-09-00143"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landry</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>St George</surname><given-names>K.</given-names></name></person-group><article-title>Laboratory Diagnosis of Zika Virus Infection</article-title><source>Arch. Pathol. Lab. Med.</source><year>2017</year><volume>141</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.5858/arpa.2016-0406-SA</pub-id><pub-id pub-id-type="pmid">27763787</pub-id></element-citation></ref><ref id="B106-viruses-09-00143"><label>106.</label><element-citation publication-type="gov"><article-title>US Food &amp; Drug Administration Emergency Use Authorizations</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika">https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-03-07">(accessed on 7 March 2017)</date-in-citation></element-citation></ref><ref id="B107-viruses-09-00143"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabe</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Staples</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hills</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wasley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Interim Guidance for Interpretation of Zika Virus Antibody Test Results</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>543</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6521e1</pub-id><pub-id pub-id-type="pmid">27254248</pub-id></element-citation></ref><ref id="B108-viruses-09-00143"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huzly</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanselmann</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schmidt-Chanasit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Panning</surname><given-names>M.</given-names></name></person-group><article-title>High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses</article-title><source>Euro Surveill.</source><year>2016</year><volume>21</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2016.21.16.30203</pub-id><pub-id pub-id-type="pmid">27126052</pub-id></element-citation></ref><ref id="B109-viruses-09-00143"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felix</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Inenami</surname><given-names>M.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pannuti</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>C.M.</given-names></name></person-group><article-title>Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection</article-title><source>J. Med. Virol.</source><year>2017</year><pub-id pub-id-type="doi">10.1002/jmv.24789</pub-id><pub-id pub-id-type="pmid">28229481</pub-id></element-citation></ref><ref id="B110-viruses-09-00143"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinhagen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Probst</surname><given-names>C.</given-names></name><name name-style="western"><surname>Radzimski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmidt-Chanasit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Emmerich</surname><given-names>P.</given-names></name><name name-style="western"><surname>van Esbroeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grobusch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Goorhuis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Warnecke</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: A multicohort study of assay performance, 2015 to 2016</article-title><source>Euro Surveill.</source><year>2016</year><volume>21</volume><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2016.21.50.30426</pub-id><pub-id pub-id-type="pmid">28006649</pub-id><pub-id pub-id-type="pmcid">PMC5291135</pub-id></element-citation></ref><ref id="B111-viruses-09-00143"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moulin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Selby</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cherpillod</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boillat-Blanco</surname><given-names>N.</given-names></name></person-group><article-title>Simultaneous outbreaks of dengue, chikungunya and Zika virus infections: Diagnosis challenge in a returning traveller with nonspecific febrile illness</article-title><source>New Microbes New Infect.</source><year>2016</year><volume>11</volume><fpage>6</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.nmni.2016.02.003</pub-id><pub-id pub-id-type="pmid">27006779</pub-id><pub-id pub-id-type="pmcid">PMC4786754</pub-id></element-citation></ref><ref id="B112-viruses-09-00143"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corman</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Rasche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baronti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aldabbagh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cadar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Pas</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Goorhuis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Molenkamp</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Assay optimization for molecular detection of Zika virus</article-title><source>Bull. World Health Organ.</source><year>2016</year><volume>94</volume><fpage>880</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.2471/BLT.16.175950</pub-id><pub-id pub-id-type="pmid">27994281</pub-id><pub-id pub-id-type="pmcid">PMC5153932</pub-id></element-citation></ref><ref id="B113-viruses-09-00143"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name></person-group><article-title>Vaccine development strategies for improving immunization: The role of modern immunology</article-title><source>Nat. Immunol.</source><year>2004</year><volume>5</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/ni0504-460</pub-id><pub-id pub-id-type="pmid">15116108</pub-id></element-citation></ref><ref id="B114-viruses-09-00143"><label>114.</label><element-citation publication-type="web"><article-title>WHO Vaccine Pipeline Tracker Zika</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/">http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-03-14">(accessed on 14 March 2017)</date-in-citation></element-citation></ref><ref id="B115-viruses-09-00143"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehrer</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M.R.</given-names></name></person-group><article-title>Tick-borne Encephalitis Vaccines</article-title><source>J. Bioterror. Biodef.</source><year>2011</year><volume>2011</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.4172/2157-2526.S1-003</pub-id><pub-id pub-id-type="pmid">23997980</pub-id><pub-id pub-id-type="pmcid">PMC3755374</pub-id></element-citation></ref><ref id="B116-viruses-09-00143"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McArthur</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M.R.</given-names></name></person-group><article-title>Japanese Encephalitis Vaccines</article-title><source>J. Bioterror. Biodef.</source><year>2011</year><volume>2</volume><pub-id pub-id-type="doi">10.4172/2157-2526.S1-002</pub-id><pub-id pub-id-type="pmid">23125946</pub-id><pub-id pub-id-type="pmcid">PMC3486421</pub-id></element-citation></ref><ref id="B117-viruses-09-00143"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larocca</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Abbink</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peron</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zanotto</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Iampietro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Badamchi-Zadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ng&#8217;ang&#8217;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirilova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nityanandam</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Vaccine protection against Zika virus from Brazil</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/nature18952</pub-id><pub-id pub-id-type="pmid">27355570</pub-id><pub-id pub-id-type="pmcid">PMC5003703</pub-id></element-citation></ref><ref id="B118-viruses-09-00143"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muruato</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>de Almeida Medeiros Daniele</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vasconcelos</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika Vaccine</article-title><source>EBioMedicine</source><year>2017</year><volume>17</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.02.003</pub-id><pub-id pub-id-type="pmid">28196656</pub-id><pub-id pub-id-type="pmcid">PMC5360567</pub-id></element-citation></ref><ref id="B119-viruses-09-00143"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbasi</surname><given-names>J.</given-names></name></person-group><article-title>First Inactivated Zika Vaccine Trial</article-title><source>JAMA</source><year>2016</year><volume>316</volume><fpage>2588</fpage><pub-id pub-id-type="doi">10.1001/jama.2016.19328</pub-id><pub-id pub-id-type="pmid">28027353</pub-id></element-citation></ref><ref id="B120-viruses-09-00143"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danko</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name></person-group><article-title>Development of dengue DNA vaccines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>7261</fpage><lpage>7266</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.019</pub-id><pub-id pub-id-type="pmid">21777640</pub-id></element-citation></ref><ref id="B121-viruses-09-00143"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ledgerwood</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Hubka</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rucker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nason</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>203</volume><fpage>1396</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir054</pub-id><pub-id pub-id-type="pmid">21398392</pub-id><pub-id pub-id-type="pmcid">PMC3080891</pub-id></element-citation></ref><ref id="B122-viruses-09-00143"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Hubka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rucker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Nason</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial</article-title><source>J. Infect. Dis.</source><year>2007</year><volume>196</volume><fpage>1732</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1086/523650</pub-id><pub-id pub-id-type="pmid">18190252</pub-id><pub-id pub-id-type="pmcid">PMC2714735</pub-id></element-citation></ref><ref id="B123-viruses-09-00143"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckett</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Tjaden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>T.</given-names></name><name name-style="western"><surname>Danko</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Tamminga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.11.050</pub-id><pub-id pub-id-type="pmid">21111785</pub-id></element-citation></ref><ref id="B124-viruses-09-00143"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbasi</surname><given-names>J.</given-names></name></person-group><article-title>Zika Vaccine Enters Clinical Trials</article-title><source>JAMA</source><year>2016</year><volume>316</volume><fpage>1249</fpage><pub-id pub-id-type="doi">10.1001/jama.2016.19328</pub-id><pub-id pub-id-type="pmid">27673295</pub-id></element-citation></ref><ref id="B125-viruses-09-00143"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowd</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Pelc</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>DeMaso</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Castilho</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Abbink</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nityanandam</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Rapid development of a DNA vaccine for Zika virus</article-title><source>Science</source><year>2016</year><volume>354</volume><fpage>237</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1126/science.aai9137</pub-id><pub-id pub-id-type="pmid">27708058</pub-id><pub-id pub-id-type="pmcid">PMC5304212</pub-id></element-citation></ref><ref id="B126-viruses-09-00143"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramps</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elbers</surname><given-names>K.</given-names></name></person-group><article-title>Introduction to RNA Vaccines</article-title><source>Methods Mol. Biol.</source><year>2017</year><volume>1499</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6481-9_1</pub-id><pub-id pub-id-type="pmid">27987140</pub-id></element-citation></ref><ref id="B127-viruses-09-00143"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richner</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Julander</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Shresta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Modified mRNA Vaccines Protect against Zika Virus Infection</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.03.016</pub-id><pub-id pub-id-type="pmid">28340344</pub-id></element-citation></ref><ref id="B128-viruses-09-00143"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salam</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Rojek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dunning</surname><given-names>J.</given-names></name><name name-style="western"><surname>Horby</surname><given-names>P.W.</given-names></name></person-group><article-title>Clinical Trials of Therapeutics for the Prevention of Congenital Zika Virus Disease: Challenges and Potential Solutions</article-title><source>Ann. Intern. Med.</source><year>2017</year><pub-id pub-id-type="doi">10.7326/M16-2530</pub-id><pub-id pub-id-type="pmid">28319995</pub-id></element-citation></ref><ref id="B129-viruses-09-00143"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adcock</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>D.H.</given-names></name></person-group><article-title>Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay</article-title><source>Antivir. Res.</source><year>2017</year><volume>138</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.018</pub-id><pub-id pub-id-type="pmid">27919709</pub-id></element-citation></ref><ref id="B130-viruses-09-00143"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balasubramanian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teramoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>R.</given-names></name></person-group><article-title>Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus</article-title><source>Antivir. Res.</source><year>2017</year><volume>137</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.015</pub-id><pub-id pub-id-type="pmid">27889529</pub-id></element-citation></ref><ref id="B131-viruses-09-00143"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrows</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Prasanth</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Schott-Lerner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Soto-Acosta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Galarza-Munoz</surname><given-names>G.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Urrabaz-Garza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection</article-title><source>Cell Host Microbe</source><year>2016</year><volume>20</volume><fpage>259</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.07.004</pub-id><pub-id pub-id-type="pmid">27476412</pub-id><pub-id pub-id-type="pmcid">PMC4993926</pub-id></element-citation></ref><ref id="B132-viruses-09-00143"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullard-Feibelman</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Govero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Veselinovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Geiss</surname><given-names>B.J.</given-names></name></person-group><article-title>The FDA-approved drug sofosbuvir inhibits Zika virus infection</article-title><source>Antivir. Res.</source><year>2017</year><volume>137</volume><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.023</pub-id><pub-id pub-id-type="pmid">27902933</pub-id><pub-id pub-id-type="pmcid">PMC5182171</pub-id></element-citation></ref><ref id="B133-viruses-09-00143"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tcw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kouznetsova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hammack</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</article-title><source>Nat. Med.</source><year>2016</year><volume>22</volume><fpage>1101</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1038/nm.4184</pub-id><pub-id pub-id-type="pmid">27571349</pub-id><pub-id pub-id-type="pmcid">PMC5386783</pub-id></element-citation></ref><ref id="B134-viruses-09-00143"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zmurko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Schols</surname><given-names>D.</given-names></name><name name-style="western"><surname>Verbeken</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaptein</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Neyts</surname><given-names>J.</given-names></name></person-group><article-title>The Viral Polymerase Inhibitor 7-Deaza-2&#8242;-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004695</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004695</pub-id><pub-id pub-id-type="pmid">27163257</pub-id><pub-id pub-id-type="pmcid">PMC4862633</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="viruses-09-00143-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">viruses-09-00143-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of anti-Zika virus (ZIKV) vaccine candidates currently in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Developers/Collaborators</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Candidate Vaccine Name (If Available)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage of Development</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Registration Number</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inactivated whole organism</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">WRAIR/BIDMC/Harvard/NIAID/Sanofi Pasteur</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Clinical (Phase 1)</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02963909">NCT02963909</ext-link></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02952833">NCT02952833</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02937233">NCT02937233</ext-link></td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">GeneOne Life Science, Inc/Inovio Pharmaceuticals</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">GLS-5700</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Clinical (Phase I)</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02809443">NCT02809443</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02887482">NCT02887482</ext-link></td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VRC/NIAID</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VRC ZIKV DNA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Clinical (Phase I)</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02840487">NCT02840487</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02996461">NCT02996461</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetic peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIAID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGS-v</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical (Phase I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03055000">NCT03055000</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measles-vectored</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Themis Bioscience</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MV-ZIKA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical (Phase I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02996890">NCT02996890</ext-link></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valera (Moderna)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-1325</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical (Phase I)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03014089">NCT03014089</ext-link></td></tr></tbody></table><table-wrap-foot><fn><p>WRAIR: Walter Reed Army Institute of Research, BIDMC: Beth Israel Deaconess Medical Center, NIAID: National Institutes of Allergy and Infectious Diseases, VRC: Vaccine Research Center.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>